<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001957.pub6" GROUP_ID="ARI" ID="725799090617020898" MERGED_FROM="" MODIFIED="2015-01-24 09:47:54 +1000" MODIFIED_BY="Liz  Dooley" NOTES="&lt;p&gt;CES comment&lt;/p&gt;&lt;p&gt;It would not be appropriate to round up the RR to two decimal places. We have consistently reported the RR to two significant figures, to ensure that its value (0.077) exactly matches the associated mean difference (7.7%).&lt;/p&gt;" NOTES_MODIFIED="2015-01-24 09:47:54 +1000" NOTES_MODIFIED_BY="Liz  Dooley" REVIEW_NO="A039" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="17.2">
<COVER_SHEET MODIFIED="2015-01-24 09:44:50 +1000" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2012-09-11 22:36:48 +1000" MODIFIED_BY="Liz Dooley" NOTES="&lt;p&gt;Unihex code 9415 (24C7)&lt;/p&gt;" NOTES_MODIFIED="2012-09-11 22:36:48 +1000" NOTES_MODIFIED_BY="Liz Dooley">Homeopathic Oscillococcinum<SUP>®</SUP> for preventing and treating influenza and influenza-like illness</TITLE>
<CONTACT>
<PERSON ID="42589628853680032254090901005159" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Robert</FIRST_NAME>
<MIDDLE_INITIALS>T</MIDDLE_INITIALS>
<LAST_NAME>Mathie</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION>Research Development Adviser</POSITION>
<EMAIL_1>rmathie@britishhomeopathic.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>British Homeopathic Association</ORGANISATION>
<ADDRESS_1>Hahnemann House</ADDRESS_1>
<ADDRESS_2>29 Park Street West</ADDRESS_2>
<CITY>Luton</CITY>
<ZIP>LU1 3BE</ZIP>
<REGION>Bedfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1582 408683</PHONE_1>
<PHONE_2>+44 1582 408675</PHONE_2>
<FAX_1>+44 1582 723032</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-01-24 09:44:50 +1000" MODIFIED_BY="Liz Dooley">
<PERSON ID="42589628853680032254090901005159" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Robert</FIRST_NAME>
<MIDDLE_INITIALS>T</MIDDLE_INITIALS>
<LAST_NAME>Mathie</LAST_NAME>
<SUFFIX>PhD</SUFFIX>
<POSITION>Research Development Adviser</POSITION>
<EMAIL_1>rmathie@britishhomeopathic.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>British Homeopathic Association</ORGANISATION>
<ADDRESS_1>Hahnemann House</ADDRESS_1>
<ADDRESS_2>29 Park Street West</ADDRESS_2>
<CITY>Luton</CITY>
<ZIP>LU1 3BE</ZIP>
<REGION>Bedfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1582 408683</PHONE_1>
<PHONE_2>+44 1582 408675</PHONE_2>
<FAX_1>+44 1582 723032</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="89442584631235903639090901011430" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Joyce</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Frye</LAST_NAME>
<SUFFIX>DO, MBA, MSCE, FACOG, ABIHM</SUFFIX>
<POSITION>Chair</POSITION>
<EMAIL_1>joyce.frye@gmail.com</EMAIL_1>
<EMAIL_2>drfrye@fusionmedicine.com, jfrye@compmed.umm.edu</EMAIL_2>
<URL/>
<MOBILE_PHONE>2153705028</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Pharmacopoeia Revision Committee</DEPARTMENT>
<ORGANISATION>Homeopathic Pharmacopoeia Convention of the United States</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Baltimore</CITY>
<ZIP>MD 21201</ZIP>
<REGION>Maryland</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>+1 410 706 6158</PHONE_1>
<PHONE_2/>
<FAX_1>+1 410 706 6210</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13022" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fisher</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Director</POSITION>
<EMAIL_1>peter.fisher@uclh.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL>www.uclh.nhs.uk/rlhh</URL>
<MOBILE_PHONE>07768194383</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Royal London Hospital for Integrated Medicine</ORGANISATION>
<ADDRESS_1>60 Great Ormond Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1N 3HR</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 20 7391 8890</PHONE_1>
<PHONE_2/>
<FAX_1>+44 20 7391 8829</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-01-24 09:44:50 +1000" MODIFIED_BY="Liz Dooley">
<UP_TO_DATE>
<DATE DAY="5" MONTH="9" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="9" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="5" MONTH="9" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-01-14 21:22:34 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-10-12 12:03:58 +1000" MODIFIED_BY="Liz  Dooley">
<DATE DAY="5" MONTH="9" YEAR="2014"/>
<DESCRIPTION>
<P>Our conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-01-14 21:22:34 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="9" YEAR="2014"/>
<DESCRIPTION>
<P>Searches conducted. We identified no new trials for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-01-14 21:23:42 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>Feedback comment and reply added to the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-01-14 21:22:47 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>Headings for Figures have been correctly labelled.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-11-21 07:16:10 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="7" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>A new team of authors has taken over this previously withdrawn review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-01-14 21:23:42 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>Due to this review update's focus on registered trademark Oscillococcinum<SUP>®</SUP>, the conclusions on prevention are based on different studies from those in previous versions of this review (i.e. <LINK REF="STD-Selkova-2005a" TYPE="STUDY">Selkova 2005a</LINK> and <LINK REF="STD-Selkova-2005b" TYPE="STUDY">Selkova 2005b</LINK> instead of <LINK REF="STD-Attena-1995" TYPE="STUDY">Attena 1995</LINK> and <LINK REF="STD-Nollevaux-1990" TYPE="STUDY">Nollevaux 1990</LINK>). Nevertheless, the results of our meta-analyses are similar to the previous publication of this review, <LINK REF="REF-Vickers-2006" TYPE="REFERENCE">Vickers 2006</LINK>, and the fundamental conclusion is unchanged: current evidence does not support a preventive effect of Oscillococcinum<SUP>®</SUP> in influenza and influenza-like illness.</P>
<P>Our focus solely on reported trial data, without reference to data or other information that was missing from the original trial reports, has had an impact on our reporting of the main outcome measure for the treatment studies. Mean duration of influenza illness cannot be extracted from the two relevant papers, <LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989 </LINK>and <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>, so patient-reported symptom relief at 48 hours is the most closely comparable primary outcome measure we can report. Again, the adjusted focus does not alter the fundamental conclusion: Oscillococcinum<SUP>®</SUP> may have a beneficial treatment effect above that of placebo but the clinical importance of any such effect is unclear. Rigorous assessment of the eligible studies has designated the evidence overall as 'low quality'.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-21 15:19:54 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-05-13 10:52:40 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="27" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>Searches conducted. Electronic literature searches were repeated in February 2006; one additional trial was found and excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-04-21 11:01:54 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="6" YEAR="2003"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="10" MONTH="3" YEAR="2003"/>
<DESCRIPTION>
<P>Response to feedback added to review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2009-05-13 10:54:40 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="4" MONTH="3" YEAR="2003"/>
<DESCRIPTION>
<P>Feedback added to review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-04-21 10:58:49 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="2" YEAR="2001"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-04-21 10:57:11 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="2" YEAR="1999"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-12-22 22:38:31 +1000" MODIFIED_BY="Robert T Mathie">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-01-24 09:47:54 +1000" MODIFIED_BY="Liz  Dooley">
<SUMMARY MODIFIED="2015-01-14 21:26:28 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-07-23 14:38:49 +1000" MODIFIED_BY="[Empty name]">Homeopathic Oscillococcinum<SUP>®</SUP> for preventing and treating influenza and influenza-like illness</TITLE>
<SUMMARY_BODY MODIFIED="2015-01-14 21:26:28 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
<BR/>To determine whether homeopathic Oscillococcinum<SUP>®</SUP> is more effective than placebo in the prevention and/or treatment of influenza and influenza-like illness in adults or children.</P>
<P>
<B>Background</B>
<BR/>Influenza ('the flu') is a highly infectious viral respiratory disease. Other than treatments for complications (such as pneumonia), the conventional medical strategies for the prevention or treatment of flu are not entirely effective or satisfactory. Oscillococcinum<SUP>®</SUP> is a highly diluted homeopathic preparation manufactured from wild duck heart and liver, which may be reservoirs of flu viruses. Some people take Oscillococcinum<SUP>®</SUP> regularly over the winter months either to prevent flu or as a treatment for flu symptoms.</P>
<P>
<B>Study characteristics</B>
<BR/>We included six studies, which comprised two prevention trials (a total of 327 young to middle-aged adults in Russia) and four treatment trials (a total of 1196 teenagers and adults in France and Germany).</P>
<P>
<B>Key results</B>
<BR/>The findings from the two prevention trials did not show that Oscillococcinum<SUP>®</SUP> can prevent the onset of flu. Although the results from the four other clinical trials suggested that Oscillococcinum<SUP>® </SUP>relieved flu symptoms at 48 hours, this might be due to bias in the trial methods. One patient reported headache after taking Oscillococcinum<SUP>®</SUP>. The evidence is current to September 2014.</P>
<P>
<B>Quality of the evidence</B>
<BR/>The overall standard of research reporting was poor, and thus many aspects of the trials' methods and results were at unclear risk of bias. We therefore judged the evidence overall as low quality, preventing clear conclusions from being made about Oscillococcinum<SUP>®</SUP> in the prevention or treatment of flu and flu-like illness.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-01-22 14:49:20 +1000" MODIFIED_BY="Liz  Dooley">
<ABS_BACKGROUND MODIFIED="2012-09-25 01:57:13 +1000" MODIFIED_BY="Robert T Mathie">
<P>Influenza is a highly infectious viral disease that is particularly common in the winter months. Oscillococcinum<SUP>®</SUP> is a patented homeopathic medicine that is made from a 1% solution of wild duck heart and liver extract, which is then serially diluted 200 times with water and alcohol.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-01-22 14:49:20 +1000" MODIFIED_BY="Liz  Dooley">
<P>To determine whether homeopathic Oscillococcinum<SUP>®</SUP> is more effective than placebo in the prevention and/or treatment of influenza and influenza-like illness in adults or children.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2014, Issue 8), MEDLINE (1966 to August week 4, 2014), MEDLINE In-Process &amp; Other Non-Indexed Citations (4 September 2014), AMED (2006 to September 2014), Web of Science (1985 to September 2014), LILACS (1985 to September 2014) and EMBASE (1980 to September 2014). We contacted the manufacturers of Oscillococcinum<SUP>®</SUP> for information on further trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-07-23 14:38:49 +1000" MODIFIED_BY="Robert T Mathie">
<P>Randomised, placebo-controlled trials of Oscillococcinum<SUP>®</SUP> in the prevention and/or treatment of influenza and influenza-like illness in adults or children.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-07-23 14:38:49 +1000" MODIFIED_BY="[Empty name]">
<P>Three review authors independently extracted data and assessed risk of bias in the eligible trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-01-14 21:57:25 +1000" MODIFIED_BY="[Empty name]">
<P>No new trials were included in this 2014 update. We included six studies: two prophylaxis trials (327 young to middle-aged adults in Russia) and four treatment trials (1196 teenagers and adults in France and Germany). The overall standard of trial reporting was poor and hence many important methodological aspects of the trials had unclear risk of bias. There was no statistically significant difference between the effects of Oscillococcinum<SUP>®</SUP> and placebo in the prevention of influenza-like illness: risk ratio (RR) 0.48, 95% confidence interval (CI) 0.17 to 1.34, P value = 0.16. Two treatment trials (judged as 'low quality') reported sufficient information to allow full data extraction: 48 hours after commencing treatment, there was an absolute risk reduction of 7.7% in the frequency of symptom relief with Oscillococcinum<SUP>® </SUP>compared with that of placebo (risk difference (RD) 0.077, 95% CI 0.03 to 0.12); the RR was 1.86 (95% CI 1.27 to 2.73; P value = 0.001). A significant but lesser effect was observed at three days (RR 1.27, 95% CI 1.03 to 1.56; P value = 0.03), and no significant difference between the groups was noted at four days (RR 1.11, 95% CI 0.98 to 1.27; P value = 0.10) or at five days (RR 1.06, 95% CI 0.96 to 1.16; P value = 0.25). One of the six studies reported one patient who suffered an adverse effect (headache) from taking Oscillococcinum<SUP>®</SUP>.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-09-27 00:09:31 +1000" MODIFIED_BY="Robert T Mathie">
<P>There is insufficient good evidence to enable robust conclusions to be made about Oscillococcinum<SUP>®</SUP> in the prevention or treatment of influenza and influenza-like illness. Our findings do not rule out the possibility that Oscillococcinum<SUP>®</SUP> could have a clinically useful treatment effect but, given the low quality of the eligible studies, the evidence is not compelling. There was no evidence of clinically important harms due to Oscillococcinum<SUP>®</SUP>.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-01-23 12:11:59 +1000" MODIFIED_BY="Liz  Dooley">
<BACKGROUND MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="[Empty name]">
<P>Influenza is a highly infectious and prevalent viral disease that is particularly common in the autumn and winter months in temperate regions of the world; annual epidemics are associated, worldwide, with three to five million cases of severe disease and one quarter to half a million deaths per annum (<LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>). In high-income countries, most deaths occur among people aged 65 or older. The 2008-2009 pandemic strain of H1N1 ('swine flu') virus was highly infectious but of relatively low pathogenicity. However, the risk of a pandemic of a more virulent H5N1 ('avian flu') strain persists. Though several prescription-only agents can prevent or reduce the duration of influenza, much influenza is treated in the community without the involvement of a physician.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Oscillococcinum<SUP>®</SUP> is a patented homeopathic medicine that is commercially available over-the-counter in many countries. The rationale for its use in influenza is not the standard homeopathic principle of 'let like be cured by like', but the related principle of 'isopathy': that a medicine derived from the causative agent of the disease, or from a product of the disease process, is used to treat the condition (<LINK REF="REF-Swayne-2000" TYPE="REFERENCE">Swayne 2000</LINK>). The medicine is manufactured from wild duck's heart and liver, which may be reservoirs and vectors of influenza viruses (<LINK REF="REF-CDCP-2010" TYPE="REFERENCE">CDCP 2010</LINK>; <LINK REF="REF-Watanabe-2011" TYPE="REFERENCE">Watanabe 2011</LINK>; <LINK REF="REF-Woo-2011" TYPE="REFERENCE">Woo 2011</LINK>).</P>
<P>Homeopathic medicines are prepared in a flask by a process of serial dilution with succussion (vigorous shaking with impact against an elastic stop) at each stage. Oscillococcinum<SUP>®</SUP> is made by the 'Korsakovian' or single-flask method. An extract of the duck liver and heart (<I>Anas barbariae hepatis et cordis extractum</I> HPUS) is shaken in a flask and then poured off. A water/alcohol mixture is added to dilute the liquid, which remains on the walls of the flask (approximately 1%). This new dilution is succussed and poured off. The process is carried out serially a total of 200 times, to give a '200K' dilution or 'potency' (<LINK REF="REF-HPUSA-2012" TYPE="REFERENCE">HPUSA 2012</LINK>).</P>
<P>The product Oscillococcinum<SUP>®</SUP> is manufactured only in the 200K formulation and by one company with exclusive rights to the 'Oscillococcinum<SUP>®</SUP>' registered trade name. A number of other preparations of <I>Anas barbariae hepatis et cordis extractum</I> are also available; their formulation is similar to that of Oscillococcinum<SUP>®</SUP> but the precise differences in extraction and preparation are unknown and so they have potentially different attributes of biological activity. </P>
</INTERVENTION>
<THEORY MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>A 200K potency is so dilute that a typical dose is unlikely to contain any molecules of the starting material (<LINK REF="REF-Kayne-2006" TYPE="REFERENCE">Kayne 2006</LINK>). The use of high dilutions, including 'ultra-molecular' dilutions such as 200K, is the reason that homeopathy is sometimes viewed as implausible.</P>
<P>Nevertheless, there is some evidence from in vitro biological models that ultra-molecular homeopathic dilutions elicit physiological effects. A total of some 1500 experiments have been reported (<LINK REF="REF-Clausen-2011" TYPE="REFERENCE">Clausen 2011</LINK>). In a systematic review of in vitro biological experiments with ultra-molecular dilutions, 73% showed biological effects; many of the experiments were of high quality (<LINK REF="REF-Witt-2007" TYPE="REFERENCE">Witt 2007</LINK>). Seventy-three per cent of replication experiments were positive, though no positive experimental result was stable enough to be reproduced by all research groups. The best established such model is based on inhibition of basophil activation by high dilutions of histamine; there are multiple independent and multi-centre reproductions of this model (<LINK REF="REF-Endler-2010" TYPE="REFERENCE">Endler 2010</LINK>; <LINK REF="REF-Ste-Laudy-2009" TYPE="REFERENCE">Ste Laudy 2009</LINK>).</P>
<P>Physical research suggests that ultra-molecular homeopathic dilutions may possess anomalous water structure. Nuclear magnetic resonance (NMR) studies suggest the presence in ultra-molecular dilutions of stable supra-molecular structures, involving nanobubbles of atmospheric gases and highly ordered water around them (<LINK REF="REF-Demangeat-2004" TYPE="REFERENCE">Demangeat 2004</LINK>; <LINK REF="REF-Demangeat-2009" TYPE="REFERENCE">Demangeat 2009</LINK>). Low temperature thermoluminescence experiments on the properties of ultra-molecular dilutions show that a 'signature' of lithium is detectable in ultra-molecular lithium chloride (<LINK REF="REF-Rey-2003" TYPE="REFERENCE">Rey 2003</LINK>; <LINK REF="REF-Van-Wijk-2006" TYPE="REFERENCE">Van Wijk 2006</LINK>). Rational hypotheses have been advanced to explain the mechanism of action of homeopathic or ultra-low-dose interventions on the immune system (<LINK REF="REF-Bellavite-2007" TYPE="REFERENCE">Bellavite 2007</LINK>) or in prothrombosis (<LINK REF="REF-Eizayaga-2011" TYPE="REFERENCE">Eizayaga 2011</LINK>), but it remains unknown how such ultra-dilute physical properties might enable the physiological effects noted in the other biological models above.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>We reviewed randomised controlled trials (RCTs) of Oscillococcinum<SUP>®</SUP> for the prevention and treatment of influenza or influenza-like illness (ILI). We defined ILI as symptoms of influenza, such as cough, fever, chills and muscle pain, without a need for virological confirmation of influenza virus infection. There is uncertainty as to the extent of similarity of related preparations (see above), therefore this review focuses solely on the registered product Oscillococcinum<SUP>®</SUP>.</P>
<P>Existing prevention and treatment strategies for influenza or ILI are not entirely effective or satisfactory. Immunisation provides moderately effective protection, though evidence is lacking in adults aged 65 years or older (<LINK REF="REF-Osterholm-2011" TYPE="REFERENCE">Osterholm 2011</LINK>). There is a delay of several months between identification of the epidemic strain and the vaccine becoming available in adequate amounts (<LINK REF="REF-WHO-2006" TYPE="REFERENCE">WHO 2006</LINK>). The adamantanes, amantadine and rimantadine, are only active against influenza A, and drug resistance is widespread (<LINK REF="REF-Jefferson-2009b" TYPE="REFERENCE">Jefferson 2009b</LINK>); their use is recommended only in emergencies when all other measures have failed. Neuraminidase inhibitors (oseltamivir (Tamiflu<SUP>®</SUP>) and zanamivir (Relenza<SUP>®</SUP>) are moderately effective in reducing the duration of influenza symptoms (<LINK REF="REF-Jefferson-2009a" TYPE="REFERENCE">Jefferson 2009a</LINK>; <LINK REF="REF-Jefferson-2014" TYPE="REFERENCE">Jefferson 2014</LINK>; <LINK REF="REF-Wang-2012" TYPE="REFERENCE">Wang 2012</LINK>). They may be effective in preventing laboratory-confirmed influenza, but not ILI (<LINK REF="REF-Jefferson-2009a" TYPE="REFERENCE">Jefferson 2009a</LINK>; <LINK REF="REF-Jefferson-2014" TYPE="REFERENCE">Jefferson 2014</LINK>). Both drugs are associated with adverse effects (<LINK REF="REF-Jefferson-2014" TYPE="REFERENCE">Jefferson 2014</LINK>). Alternative or additional prevention and treatment strategies are therefore of interest.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-01-22 14:49:34 +1000" MODIFIED_BY="Liz  Dooley">
<P>To determine whether homeopathic Oscillococcinum<SUP>®</SUP> is more effective than placebo in the prevention and/or treatment of influenza and influenza-like illness in adults or children.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-01-23 12:10:56 +1000" MODIFIED_BY="Liz  Dooley">
<SELECTION_CRITERIA MODIFIED="2015-01-23 12:10:56 +1000" MODIFIED_BY="Liz  Dooley">
<CRIT_STUDIES MODIFIED="2012-09-08 02:14:32 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) with a placebo control.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-07-23 14:38:49 +1000" MODIFIED_BY="Robert T Mathie">
<P>Patients of any age (adults or children) wishing to prevent, or presenting with, influenza or ILI (symptoms of influenza such as cough, fever, chills and muscle pain, in the absence of virological evidence of infection).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Oscillococcinum<SUP>®</SUP> in any regime. All other formulations of <I>Anas barbariae hepatis et cordis extractum</I> and medicines made from homeopathically prepared influenza virus, influenza vaccine or avian liver, are not included. Previous versions of this review, <LINK REF="REF-Vickers-2000" TYPE="REFERENCE">Vickers 2000</LINK>, <LINK REF="REF-Vickers-2004" TYPE="REFERENCE">Vickers 2004</LINK> and <LINK REF="REF-Vickers-2006" TYPE="REFERENCE">Vickers 2006</LINK>, included one study on '<I>Anas barbariae</I> 200 CH' that was not defined by the authors as Oscillococcinum<SUP>® </SUP>(<LINK REF="STD-Attena-1995" TYPE="STUDY">Attena 1995</LINK>); as stated above (<LINK TAG="INTERVENTION" TYPE="SECTION">Description of the intervention</LINK>), such a preparation may have properties that differ importantly from those of true Oscillococcinum<SUP>®</SUP>. Previous versions of the review also included two studies on Mucococcinum (<LINK REF="STD-Nollevaux-1990" TYPE="STUDY">Nollevaux 1990</LINK>; <LINK REF="STD-Rottey-1995" TYPE="STUDY">Rottey 1995</LINK>), a preparation comprising a variety of inactivated viruses and bacteria prepared homeopathically to a 200K potency, which is clearly different from Oscillococcinum<SUP>®</SUP>.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-01-23 12:10:56 +1000" MODIFIED_BY="Liz  Dooley">
<P>Any measure of influenza severity or duration, except laboratory findings (for example, antibody titres).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-10-12 12:28:22 +1000" MODIFIED_BY="Liz  Dooley">
<P>Primary outcome measures for prophylaxis studies:</P>
<UL>
<LI>Occurrence of influenza (either symptomatic or laboratory-confirmed)</LI>
</UL>
<P>Primary outcome measures for treatment studies:</P>
<UL>
<LI>Patient-reported absence of influenza symptoms at 48 hours</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-01-23 12:10:56 +1000" MODIFIED_BY="Liz  Dooley">
<P>Secondary outcome measures for prophylaxis studies:</P>
<UL>
<LI>Adverse events</LI>
</UL>
<P>Secondary outcome measures for treatment studies:</P>
<UL>
<LI>Adverse events</LI>
<LI>Physician assessment of symptoms at 48 hours</LI>
<LI>Patient-reported symptom relief after more than 48 hours</LI>
<LI>Concomitant medication</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-01-14 21:31:26 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-01-14 21:31:26 +1000" MODIFIED_BY="[Empty name]">
<P>For this 2014 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 8) (accessed 5 September 2014), which contains the Acute Respiratory Infections Group's Specialised Register, MEDLINE (July 2012 to August week 4, 2014), MEDLINE In-Process &amp; Other Non-Indexed Citations (4 September 2014), AMED (August 2012 to September 2014), Web of Science (August 2012 to September 2014), LILACS (August 2012 to September 2014) and EMBASE (August 2012 to September 2014). Previously we searched CENTRAL (2012, Issue 7), MEDLINE (Ovid) (January 2006 to July week 4, 2012), MEDLINE In-Process &amp; Other Non-Indexed Citations (6 August 2012), AMED (2006 to August 2012), Web of Science (1985 to August 2012), LILACS (1982 to August 2012) and EMBASE.com (January 2006 to August 2012). There were no language or publication restrictions. (Details of earlier searches are in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<P>We used the search strategy described in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> to search MEDLINE and CENTRAL. We combined the MEDLINE search strategy with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We adapted the terms to search the other databases (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov trials registries for completed and ongoing studies (latest search 8 September 2014). We contacted the manufacturers of Oscillococcinum<SUP>®</SUP> for information, which was provided. The manufacturers of Oscillococcinum<SUP>®</SUP> were aware of one paper, originally published in Russian in 2005, which is a randomised controlled trial of the preventive effects of Oscillococcinum<SUP>®</SUP> in influenza. This paper has been translated into English and its findings are reflected in this review update.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-01-14 21:34:15 +1000" MODIFIED_BY="[Empty name]">
<P> </P>
<STUDY_SELECTION MODIFIED="2012-03-13 16:24:20 +1000" MODIFIED_BY="Robert T Mathie">
<P>The three review authors independently applied prospective inclusion and exclusion criteria to the literature identified. There were no disagreements about study inclusion. In particular, there was no dissent in the decision to include only those studies that investigated trademarked Oscillococcinum<SUP>®</SUP>.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-10-30 20:16:49 +1000" MODIFIED_BY="Robert T Mathie">
<P>The three review authors independently extracted data. We extracted the following data on the trial participants from included trials: inclusion and exclusion criteria and method and place of recruitment (for example, primary care). We extracted separately, by group, the following data on trial participants: number randomised, number of withdrawals, age and gender. We recorded, by group, the number of participants and number of events, or the mean and standard deviation (SD) for each outcome measure. We turned ordinal scales into binomial variables by regarding each participant as 'improved' or 'not improved', as appropriate. If variables were reported more than once per follow-up day, we selected the results for the evening thereof. We recorded details of the treatment given and adverse events reported for the experimental and comparison groups.</P>
<P>In this update, we did not attempt to contact trial authors to provide data or other information that was missing from their trial reports. 'Mean time to recovery' (the main outcome measure selected by the authors of the previous versions of this review) cannot be extracted from the original trial reports, and so 'absence of patient-assessed influenza symptoms at 48 hours' was the most appropriate measure available to us as 'primary outcome' - see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>. As was the case in previous versions of the review, both published and unpublished studies were eligible for data extraction (see <LINK TAG="ELECTRONIC_SEARCHES" TYPE="SECTION">Electronic searches</LINK>); thus, our adjusted approach does not render this review update any more or less prone to publication bias than its predecessors. We contacted the manufacturers of Oscillococcinum<SUP>®</SUP> for trial reports. We resolved disagreements between review authors by consensus.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>We used the following methodological categories to appraise each paper:</P>
<OL>
<LI>Sequence generation (was the allocation sequence adequately generated by, for example, a computerised random number generator?)</LI>
<LI>Allocation concealment of treatment (was treatment allocation concealed until each new patient had been unambiguously entered into the trial?)</LI>
<LI>Blinding of (a) participants and personnel; and (b) blinding of outcome assessors (was knowledge of the allocated interventions adequately prevented during the study?)</LI>
<LI>Incompleteness of outcome data (were incomplete or missing outcome data adequately addressed? Were there systematic differences in withdrawals from the trial?)</LI>
<LI>Free from selective reporting (have all the measures described in the paper's Methods been reported in the Results?)</LI>
<LI>Other potential threats to validity (was the study apparently free of other problems that could put it at risk of bias? (e.g. was there extreme baseline imbalance in the groups' participants?)).</LI>
</OL>
<P>We judged each category using the Cochrane 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). 'Low risk' of bias indicates our opinion that the plausibly postulated bias was unlikely to alter the results seriously; 'high risk' of bias, on the other hand, indicates that plausibly postulated bias seriously weakened our confidence in the results. We judged a category 'unclear risk' if there was insufficient or no information on which to assess whether or not an important risk of bias existed. Two review authors (RTM, JF) independently judged each trial. After the first independent assessments, there was 64% accord between the two review authors across all six categories for the seven eligible papers. We readily resolved the areas of disagreement by discussion, including input from the third review author (PF).</P>
<P>No trial was excluded from the review if we judged it 'high risk of bias', but we regarded the findings from any such trial with increased caution.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-01-14 21:34:15 +1000" MODIFIED_BY="[Empty name]">
<P>We used relative treatment effect (risk ratio, RR) as the measure of choice (dichotomous data). For primary outcomes (in cases for which the RR data showed a statistically significant difference), we then also examined the absolute risk reduction (risk difference, RD). We calculated number needed to treat to benefit (NNTB) in the standard way, as a reciprocal of the risk difference. At a population level, there would be significant social gains from at least a 5% difference in the proportion of individuals prevented from acquiring influenza symptoms or in the proportion of those achieving symptom relief at 48 hours (see <LINK TAG="IMPLICATIONS_PRACTICE" TYPE="SECTION">Implications for practice</LINK>). We therefore regard the minimal clinically important benefit as a difference of 5% favouring Oscillococcinum<SUP>® </SUP>(i.e. RD <U>&gt;</U> 0.05, corresponding to NNTB <U>&lt;</U> 20). Correspondingly, we regard the minimal clinically important harm as a difference of 5% favouring placebo.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-01-02 08:57:30 +1000" MODIFIED_BY="Robert T Mathie">
<P>All eligible trials were of parallel-group design. There were no issues in connection with non-standard designs, such as cross-over trials and cluster-randomised trials.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>We noted missing data in the description of each trial. In all analyses, we have used the per-protocol sample sizes in order to remain consistent with the data presentation and analyses in the original papers.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>We used the fixed-effect meta-analysis model by default. We used the random-effects model in cases where statistical heterogeneity was evident (visually, where I<SUP>2</SUP> statistic &gt; 50% and/or where Chi<SUP>2</SUP> &gt; number of degrees of freedom (df)). In such cases, we applied the more conservative of the two results.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-08-21 00:32:43 +1000" MODIFIED_BY="Robert T Mathie">
<P>We have not specifically addressed publication bias in view of the detailed 'Risk of bias' assessment per trial and the small number of eligible trials overall.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>We assumed there was sufficient clinical homogeneity in influenza symptoms and in the prescription of Oscillococcinum<SUP>®</SUP> in the trials to enable the fixed-effect meta-analysis model to be used by default (see also <LINK TAG="HETEROGENEITY_ASSESSMENT" TYPE="SECTION">Assessment of heterogeneity</LINK>). We usually considered a meta-analysis was appropriate when a given type of data was available from more than a single trial report.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>We analysed prophylaxis and treatment trials in two distinct categories, with the investigation of heterogeneity for each particular analysis carried out as above.</P>
<P>One paper presented subgroup analyses on the effect of age of patient and severity of symptoms after 48 hours of treatment (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>); that analysis was not a planned part of the study's protocol. We undertook Chi<SUP>2</SUP> analysis on these data to examine more directly the comparative influence of younger/older age and of illness severity on symptom relief at 48 hours.<BR/>
</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-01-02 09:05:39 +1000" MODIFIED_BY="Robert T Mathie">
<P>We did not carry out sensitivity analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-01-23 12:11:59 +1000" MODIFIED_BY="Liz  Dooley">
<STUDY_DESCRIPTION MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>For this 2014 update, we obtained a total of 453 records from the electronic database searches. We identified no new trials for inclusion.</P>
<SEARCH_RESULTS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Each of the six eligible trials (see below) reported outcomes that reflected the presence or absence of influenza or ILI, compatible with our designated primary outcomes both for prophylaxis and treatment studies.</P>
<P>For prophylaxis trials, 'number of subjects who fell ill' was the common outcome identifiable across the two studies concerned (<LINK REF="STD-Selkova-2005a" TYPE="STUDY">Selkova 2005a</LINK>; <LINK REF="STD-Selkova-2005b" TYPE="STUDY">Selkova 2005b</LINK>). Neither study reported adverse events.</P>
<P>For treatment trials, symptom relief was reported in a number of different ways. Indeed, a primary outcome measure was defined clearly by the original authors in just one of the treatment studies (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>): the proportion of patients that reported absence of symptoms (complete resolution of five defined cardinal symptoms and rectal temperature &lt; 37.5 °C) within 48 hours of treatment with Oscillococcinum<SUP>®</SUP>. The same paper examined patient-reported symptom relief over a period of seven days following treatment, while other treatment trials, including <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>, selected two to five days or more. Physician assessments of symptoms at 48 hours were also used in one paper (<LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>). Both these treatment trials could be included in a meta-analysis of the primary outcome measure: patient-assessed absence of influenza symptoms at 48 hours after receiving Oscillococcinum<SUP>®</SUP> or placebo (see also Notes in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>: <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>).</P>
<P>As secondary outcomes from treatment, we have included 'proportion of patients reporting absence of symptoms by three days of treatment', 'proportion of patients reporting absence of symptoms by four days of treatment' and 'proportion of patients reporting absence of symptoms by five days of treatment'. Three trials reported outcomes for individual symptoms of influenza, such as fever, chills, aches or cough (<LINK REF="STD-Casanova-1984" TYPE="STUDY">Casanova 1984</LINK>; <LINK REF="STD-Casanova-1988" TYPE="STUDY">Casanova 1988</LINK>; <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>).</P>
<P>Additional secondary outcomes from the treatment studies included: physician-assessed absence of symptoms at 48 hours; physician-assessed improvement at 48 hours (see also Notes in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table: <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>); use of concomitant medication (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>; <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>). Only one study assessed and reported adverse events (<LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>We included six studies in this review: two prophylaxis trials, published in a single paper by Selkova (<LINK REF="STD-Selkova-2005a" TYPE="STUDY">Selkova 2005a</LINK>; <LINK REF="STD-Selkova-2005b" TYPE="STUDY">Selkova 2005b</LINK>), with a total of 327 participants, and four treatment trials (<LINK REF="STD-Casanova-1984" TYPE="STUDY">Casanova 1984</LINK>; <LINK REF="STD-Casanova-1988" TYPE="STUDY">Casanova 1988</LINK>; <LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>; <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>), with a total of 1196 participants. All six trials compared trademarked Oscillococcinum<SUP>®</SUP> (Boiron) to a placebo.</P>
<P>Only one of the treatment trials explicitly reported that participants were accrued during an outbreak of influenza (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>). Participants were generally recruited from primary care settings. Some trials included both children (older than 12 years) and adults. Inclusion and exclusion criteria were sometimes not described. In two of the four treatment trials, participants had to meet a defined standard for influenza-like illness (for example, rectal temperature greater than 38 °C and at least two episodes of headache, stiffness, lumbar and articular pain or shivers). Exclusion criteria in these two trials were prior duration of symptoms for longer than 24 hours, immune deficiency, influenza vaccination or immunostimulant treatment.</P>
<P>Details are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Three studies included in the previous version of the review, <LINK REF="REF-Vickers-2006" TYPE="REFERENCE">Vickers 2006</LINK>, have been excluded in this update because we have now focused solely on patented Oscillococcinum<SUP>®</SUP>. <LINK REF="STD-Attena-1995" TYPE="STUDY">Attena 1995</LINK> used a 200C potency of extract of liver and heart from <I>Anas barbariae</I> (not Oscillococcinum<SUP>®</SUP>); it was published as a letter to the Editor of a peer-reviewed journal. <LINK REF="STD-Nollevaux-1990" TYPE="STUDY">Nollevaux 1990</LINK> and <LINK REF="STD-Rottey-1995" TYPE="STUDY">Rottey 1995</LINK> used a preparation of inactivated viruses and bacteria prepared to a 200K potency.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-01-14 21:37:49 +1000" MODIFIED_BY="[Empty name]">
<P>The standard of trial reporting was poor or very poor. In only two trials was there sufficient information to enable data extraction of the main outcome (defined above), though some of the necessary data were extractable solely from the graphical illustrations in those papers (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>; <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>). Four studies were published in the non-peer-reviewed literature, in France or in Russia (<LINK REF="STD-Casanova-1984" TYPE="STUDY">Casanova 1984</LINK>; <LINK REF="STD-Casanova-1988" TYPE="STUDY">Casanova 1988</LINK>; <LINK REF="STD-Selkova-2005a" TYPE="STUDY">Selkova 2005a</LINK>; <LINK REF="STD-Selkova-2005b" TYPE="STUDY">Selkova 2005b</LINK>). One of the above trials was reported in a general medical magazine rather than in a scientific journal; accordingly, this trial was reported very briefly and most of the important experimental details were missing (<LINK REF="STD-Casanova-1984" TYPE="STUDY">Casanova 1984</LINK>). No details of exclusions and withdrawals were given in four trials (<LINK REF="STD-Casanova-1984" TYPE="STUDY">Casanova 1984</LINK>; <LINK REF="STD-Casanova-1988" TYPE="STUDY">Casanova 1988</LINK>; <LINK REF="STD-Selkova-2005a" TYPE="STUDY">Selkova 2005a</LINK>; <LINK REF="STD-Selkova-2005b" TYPE="STUDY">Selkova 2005b</LINK>). The sample sizes in the trials by <LINK REF="STD-Selkova-2005a" TYPE="STUDY">Selkova 2005a</LINK>, <LINK REF="STD-Casanova-1984" TYPE="STUDY">Casanova 1984</LINK> and <LINK REF="STD-Casanova-1988" TYPE="STUDY">Casanova 1988</LINK> are suspiciously round numbers (100, 100, 300 respectively).</P>
<P>Overall, the extent of methodological bias in this set of trials is difficult to determine, as illustrated by the high frequency of the judgement 'unclear' using the 'Risk of bias' tool in <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK> (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Specific examples of plausible bias per assessment domain are given below.</P>
<ALLOCATION MODIFIED="2012-07-24 15:52:41 +1000" MODIFIED_BY="Robert T Mathie">
<P>The procedures for sequence generation and allocation concealment were adequately reported in just one paper (<LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>). Allocation procedures were not reported in any of the other papers; risk of bias arising from such deficiencies of reporting and/or prosecution of the trials is therefore impossible to ascertain.</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-07-23 14:38:50 +1000" MODIFIED_BY="Robert T Mathie">
<P>Blinding of participants and personnel was generally adequate overall, explicitly so in two trials (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>; <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>). Homeopathic medicines are generally impossible to distinguish from matching placebos because they have no inherent taste, smell or obvious adverse effects such as dry mouth, and this also is the case for Oscillococcinum<SUP>®</SUP>. Thus it is unlikely that bias from this source was introduced during the trials. Adequacy of blinding of outcome assessment was unclear for all trials.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>We judged only one trial at low risk of bias in this domain (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>). In one study, up to 10% of participants did not complete the trial; moreover, the paper did not describe details of the group-specific reasons for drop-out and attrition numbers throughout the paper are confused and confusing (<LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>). We assessed <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK> as having 'unclear' risk of attrition bias, as well as all the remaining studies.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>All studies were 'unclear' risk of bias in this assessment domain. Amongst other areas of lack of clarity, in one of the papers the authors state that statistical analysis was "based on the mean date of elimination of symptoms" but their graphical and statistical data do not reveal such a time point; nor is it possible to extract data from the information provided in the paper (<LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>). Without making a number of assumptions about the precise data, it is also not possible to derive 'mean time to recovery from symptoms' from the other trial that presented time-related information (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>). Other concerns about statistical analysis/presentation in those two papers are summarised in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>Another research group conducted two trials (<LINK REF="STD-Casanova-1984" TYPE="STUDY">Casanova 1984</LINK>; <LINK REF="STD-Casanova-1988" TYPE="STUDY">Casanova 1988</LINK>). The first of those trials reported data for patient assessment, chills, aches, rhinitis, night cough, day cough and fever; the second trial reported data only for temperature, chills and aches. We do not know if data on rhinitis, cough and patient assessment were recorded in the second trial but not reported. Moreover, the length of follow-up varied between the two trials. The first reported data for day eight; the second for day four. We do not know if data were recorded daily but only the most favourable comparisons were reported. Given those considerations, the outcomes for individual symptoms are more likely to be biased than those for presence or absence of influenza or use of concomitant medication.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Only two of the trials presented baseline information about the study participants (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>; <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>). We nevertheless labelled <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK> 'unclear' risk of bias in this domain because of shortfalls in the clarity of its statistical presentation (see also <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-01-23 12:11:59 +1000" MODIFIED_BY="Liz  Dooley" NOTES="&lt;p&gt;Can we calculate these?&lt;/p&gt;" NOTES_MODIFIED="2015-01-23 12:11:59 +1000" NOTES_MODIFIED_BY="Liz  Dooley">
<SUBSECTION>
<HEADING LEVEL="3">Prophylaxis trials</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Occurrence of influenza</HEADING>
<P>The data on occurrence of influenza-like illness displayed considerable heterogeneity between trials (Chi<SUP>2</SUP> = 1.49, df = 1; I<SUP>2</SUP> statistic = 33%). Using a random-effects model for statistical analysis, the mean risk ratio (RR) of influenza-like illness occurring in participants receiving treatment was 0.48 (95% confidence interval (CI) 0.17 to 1.34; P value = 0.16) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Adverse events were not reported in either of the eligible trials.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment trials</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Patient-reported absence of symptoms at 48 hours</HEADING>
<P>Data from two trials showed that the mean RR for symptom absence was 1.86 (95% CI 1.27 to 2.73) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), statistically significant in favour of Oscillococcinum<SUP>®</SUP> (P value = 0.001; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). The two trials comprised a total of 796 participants. The mean proportion of patients who reported absence of influenza symptoms was 36/401 (= 9.0%) in the placebo groups and 66/395 (= 16.7%) in the Oscillococcinum<SUP>®</SUP> groups (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>; <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>), a mean difference of 7.7%. Correspondingly, the risk difference (RD) was 0.077 (95% CI 0.03 to 0.12) and so the number needed to treat to benefit (NNTB) was 13 (95% CI 9 to 34); the 95% confidence limits include the pre-defined minimal clinically important benefit (RD 0.05, NNTB 20) - see <LINK TAG="EFFECT_MEASURES" TYPE="SECTION">Measures of treatment effect</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="6">Subgroup analysis</HEADING>
<UL>
<LI>
<B>Effect of age of patient</B> (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>): for participants aged 12 to 29 years, the effect of Oscillococcinum<SUP>®</SUP> was RR 3.08, 95% CI 1.32 to 7.23, whereas for participants aged &gt; 30 years, the effect was RR 1.26, 95% CI 0.59 to 2.70. Direct comparison between the two groups of participants showed that the higher frequency of symptom absence in younger participants did not reach the level of statistical significance (Chi<SUP>2</SUP> = 3.188; P value = 0.07).</LI>
<LI>
<B>Effect of severity of illness</B> (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>): for participants with mild to moderate symptoms, the effect of Oscillococcinum<SUP>®</SUP> was RR 2.08, 95% CI 1.19 to 3.61, whereas for participants with severe symptoms, the effect was RR 0.88, 95% CI 0.33 to 2.32. Direct comparison between the two groups of participants showed that symptom relief did not occur significantly more frequently in the subgroup with mild to moderate symptoms compared to those with severe symptoms (Chi<SUP>2</SUP> = 1.784; P value = 0.18).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Patient-reported absence of specified symptoms at 48 hours</HEADING>
<P>Data are derived from the trials reported by <LINK REF="STD-Casanova-1984" TYPE="STUDY">Casanova 1984</LINK>, <LINK REF="STD-Casanova-1988" TYPE="STUDY">Casanova 1988</LINK> and/or <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>.</P>
<P>Fitness for work at day two is presented in <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> (RR 1.80, 95% CI 0.99 to 3.26; P value = 0.05). Fitness for work at day four is shown in <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK> (RR 1.04, 95% CI 0.83 to 1.30; P value = 0.74).</P>
<P>Results for individual symptoms (each reported at 48 hours) are presented in Analyses 2.6 to 2.17. Most analyses showed symptom changes in favour of Oscillococcinum<SUP>®</SUP>: <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK> (no chills: 1.30, 95% CI 1.04 to 1.63; P value = 0.02); <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK> (no fever: 1.98, 95% CI 1.34 to 2.92; P value = 0.0006); <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK> (no general aches: 1.73, 95% CI 1.16 to 2.59; P value = 0.007); <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK> (no backache: 1.27, 95% CI 1.00 to 1.61; P value = 0.05); <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK> (no spinal pain: 1.27, 95% CI 1.02 to 1.58; P value = 0.03); <LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK> (no muscle pain: 1.47, 95% CI 1.10 to 1.97; P value = 0.01); <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK> (no articular pain: 1.40, 95% CI 1.09 to 1.80; P value = 0.009); <LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK> (no day cough: 2.00, 95% CI 1.20 to 3.31; P value = 0.008); <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK> (temperature: mean difference -0.50 degrees, 95% CI -0.67 to -0.33; P value &lt; 0.00001). The remaining analyses showed symptom changes in favour of placebo: <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK> (no rhinitis: RR 1.33, 95% CI 0.66 to 2.70; P value = 0.42); <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK> (no headache: 1.20, 95% CI 0.88 to 1.63; P value = 0.25); <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK> (no night cough: 1.44, 95% CI 0.73 to 2.84; P value = 0.29).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>One patient taking Oscillococcinum<SUP>®</SUP> reported a headache that 'might' have been due to the trial medication (<LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>). None of the other eligible trials of Oscillococcinum<SUP>®</SUP> reported adverse events (<LINK REF="STD-Casanova-1984" TYPE="STUDY">Casanova 1984</LINK>; <LINK REF="STD-Casanova-1988" TYPE="STUDY">Casanova 1988</LINK>; <LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Physician assessment of symptoms at 48 hours</HEADING>
<P>Physician assessment of improvement in symptoms at 48 hours was reported in one paper (<LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>): mean RR in favour of Oscillococcinum<SUP>®</SUP> was 1.07, 95% CI 0.98 to 1.18, which is not statistically significant (P value = 0.13) (<LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>). Physician assessment of participants' absence of symptoms at 48 hours was reported in one paper (<LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>): mean RR in favour of Oscillococcinum<SUP>®</SUP> was 1.28, 95% CI 0.79 to 2.06, which is not statistically significant (P value = 0.31) (<LINK REF="CMP-002.19" TYPE="ANALYSIS">Analysis 2.19</LINK>).</P>
<P>
<B>Patient-reported symptom relief after more than 48 hours</B>
</P>
<UL>
<LI>Day 3 (<LINK REF="CMP-002.20" TYPE="ANALYSIS">Analysis 2.20</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>): the RR of relief from influenza symptoms was 1.27, 95% CI 1.03 to 1.56, statistically significantly in favour of Oscillococcinum<SUP>®</SUP> (P value = 0.03).</LI>
<LI>Day 4 (<LINK REF="CMP-002.21" TYPE="ANALYSIS">Analysis 2.21</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>): the RR of relief from influenza symptoms was 1.11, 95% CI 0.98 to 1.27, which is not statistically significant (P value = 0.10).</LI>
<LI>Day 5 (<LINK REF="CMP-002.22" TYPE="ANALYSIS">Analysis 2.22</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>): the RR of relief from influenza symptoms was 1.06, 95% CI 0.96 to 1.16, which is not statistically significant (P value = 0.25).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Concomitant medication</HEADING>
<P>There was less increased use of concomitant medication over the trial period in the Oscillococcinum<SUP>®</SUP> group compared with the placebo group: RR 0.61, 95% CI 0.40 to 0.92; P value = 0.02 (<LINK REF="CMP-002.23" TYPE="ANALYSIS">Analysis 2.23</LINK>). Medication use for pain or fever was significantly less in the Oscillococcinum<SUP>®</SUP> group: RR 0.82, 95% CI 0.67 to 1.00; P value = 0.05 (<LINK REF="CMP-002.24" TYPE="ANALYSIS">Analysis 2.24</LINK>). There was no inter-group difference in the use of medication for cough or coryza: RR 0.96, 95% CI 0.76 to 1.21; P value = 0.72 (<LINK REF="CMP-002.25" TYPE="ANALYSIS">Analysis 2.25</LINK>) or of antibiotics: RR 0.87, 95% CI 0.47 to 1.62; P value = 0.67 (<LINK REF="CMP-002.26" TYPE="ANALYSIS">Analysis 2.26</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-01-14 21:43:14 +1000" MODIFIED_BY="[Empty name]">
<P>Overall, the risk of bias in the six included trials was unclear, and so the statistical findings from this systematic review must be viewed with caution. Only two treatment trials contained some domains that we judged to have low risk of bias (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>; <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>), but each of those trials also included domains in which lack of clarity prevented clear judgement. Due to this unclear reporting, we felt obliged to judge even these two studies 'low quality of evidence' (GRADE Working Group - see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>The evidence, which is limited to two studies with unclear risk of bias, did not support a preventive effect of Oscillococcinum<SUP>®</SUP> in influenza and influenza-like illness (risk ratio (RR) 0.48, 95% confidence interval (CI) 0.17 to 1.34; P value = 0.16). The results were skewed by the extremely diverse data reported in the two prophylaxis studies (<LINK REF="STD-Selkova-2005a" TYPE="STUDY">Selkova 2005a</LINK>; <LINK REF="STD-Selkova-2005b" TYPE="STUDY">Selkova 2005b</LINK>); the larger of the two trials (n = 227) obtained positive findings. Further prophylaxis research on Oscillococcinum<SUP>®</SUP> might thus be indicated. Since the single eligible prophylaxis paper to date did not report adverse events, any new research in this area should include such assessment. This is especially important given the high frequency of adverse reactions reported in a non-eligible prophylaxis trial on an Oscillococcinum-like homeopathic product (<LINK REF="STD-Attena-1995" TYPE="STUDY">Attena 1995</LINK>).</P>
<P>Oscillococcinum<SUP>®</SUP> appeared to have a modest effect on influenza and influenza-like illness in the first two days of treatment (as assessed by the patient). At 48 hours, the RR of 1.86 (95% CI 1.27 to 2.73) indicated a statistically significant effect of Oscillococcinum<SUP>®</SUP>, and the 95% CIs of the risk difference (RD) (0.03 to 0.12) and the number needed to treat to benefit (NNTB) (9 to 34) suggested that the additional treatment benefit would potentially be of clinical importance at population level (limits defined as RD 0.05, NNTB 20). Four to five days after the start of treatment, the difference between Oscillococcinum<SUP>®</SUP> and placebo dwindled to statistical non-significance, which may be deemed consistent with the self limiting natural course of the illness.</P>
<P>The limited available evidence suggested that, at 48 hours, the following symptoms were most responsive to treatment: chills, fever, general aches, backache, spinal pain, muscle pain, articular pain and day cough. A key limitation in interpreting these findings is that one of the trials was not published in a standard medical journal, contained little experimental detail, did not report withdrawals and analysed a suspiciously rounded number of participants (<LINK REF="STD-Casanova-1984" TYPE="STUDY">Casanova 1984</LINK>).</P>
<P>There were data from only one trial on the effects of Oscillococcinum<SUP>®</SUP> with respect to age of patient or severity of illness (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>). Though <LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK> found a better response to treatment at 48 hours in people aged less than 30 years and in participants with less severe symptoms, these findings were based on unplanned subgroup analyses; our Chi<SUP>2 </SUP>test analyses did not support the researchers' original conclusions.</P>
<P>Although there were insufficient data to determine clearly the effect of Oscillococcinum<SUP>®</SUP> on concomitant medication, one trial noted a lesser increase in the overall use of concomitant medication during the study period (<LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>), while another trial reported a decreased use of analgesic and antipyretic medication (<LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK>).</P>
<P>It is obvious that doubts remain about the reliability and the clinical importance of the findings reported. A question as scientifically controversial as whether or not a highly diluted homeopathic medicine is equivalent to placebo will require many more statistically robust data. As adjudged above, further research is very likely to have an important impact on the confidence in, and the magnitude of, the estimate of treatment effects (GRADE Working Group grade of evidence: low quality). To confirm or refute the existing evidence, it is therefore concluded that additional research on Oscillococcinum<SUP>®</SUP> prevention and/or treatment is necessary - see <LINK TAG="CONCLUSIONS" TYPE="SECTION">Authors' conclusions</LINK> below.</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-01-14 20:39:30 +1000" MODIFIED_BY="[Empty name]">
<P>The evidence from two studies with unclear risk of bias did not support a significant preventive effect of Oscillococcinum<SUP>® </SUP>(RR 0.48, 95% CI 0.17 to 1.34; P value = 0.16). Two studies with low quality of evidence suggested that 48 hours after commencing treatment, the effect of Oscillococcinum<SUP>®</SUP> on patient-reported symptom relief was significantly greater than that of placebo (RR 1.86, 95% CI 1.27 to 2.73; P value = 0.001); the RD was 0.077, 95% CI 0.03 to 0.12, indicating that at population level the symptom improvement in early influenza-like illness (ILI) might potentially be clinically useful. There was no evidence of clinically important harms. Adverse effects of the intervention have been reported by one patient in one study.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>The trials reviewed here were sampled from general primary care populations and did not specifically focus on target sub-populations for treatment of influenza, such as individuals with severe disease or at high risk of complications, including older people, pregnant and post-partum women and those with chronic medical conditions. The incidence of complications of ILI in such groups, and indeed the general population, is of interest but was not investigated in the trials reviewed.</P>
<P>As discussed above, the intervention covered by this review is narrower than in the previous versions: it includes only trademarked Oscillococcinum<SUP>®</SUP>, whereas the earlier versions included other, similar, products. However, Oscillococcinum<SUP>®</SUP> is the most widely used product and has been the subject of considerable research. In one of the papers included in the previous versions (but which we have excluded), there was ambiguity about the precise nature of the medicinal product (<LINK REF="STD-Attena-1995" TYPE="STUDY">Attena 1995</LINK>). By removing such uncertainty, we therefore believe we have included only exactly relevant interventions. </P>
<P>From the viewpoint of external validity (generalisability), it is important to note that the majority of ILIs are not true, virologically confirmed, influenza (<LINK REF="REF-Jefferson-2009a" TYPE="REFERENCE">Jefferson 2009a</LINK>). Furthermore, ILI and laboratory-confirmed influenza are clinically indistinguishable (<LINK REF="REF-Call-2005" TYPE="REFERENCE">Call 2005</LINK>). In the 2009-2010 influenza season in the USA, which included the H1N1 'swine flu' pandemic, overall only 21% of specimens tested positive for influenza viruses, rising to around 40% at the peak of the pandemic (<LINK REF="REF-CDCP-2011" TYPE="REFERENCE">CDCP 2011</LINK>). Clinical trials of neuraminidase inhibitors tend to include a higher proportion of true influenza than is encountered in routine practice. For people exposed to influenza, neuraminidase inhibitors reduce their chance of developing true, laboratory-confirmed, influenza, but not ILI (<LINK REF="REF-Jefferson-2009a" TYPE="REFERENCE">Jefferson 2009a</LINK>; <LINK REF="REF-Jefferson-2014" TYPE="REFERENCE">Jefferson 2014</LINK>). However, as stated, true influenza is a small component of ILI (<LINK REF="REF-Jefferson-2009a" TYPE="REFERENCE">Jefferson 2009a</LINK>). Neuraminidase inhibitors are moderately effective in shortening the duration of influenza symptoms (<LINK REF="REF-Jefferson-2009a" TYPE="REFERENCE">Jefferson 2009a</LINK>; <LINK REF="REF-Jefferson-2014" TYPE="REFERENCE">Jefferson 2014</LINK>; <LINK REF="REF-Wang-2012" TYPE="REFERENCE">Wang 2012</LINK>). Regarding neuraminidase inhibitors in epidemic and pandemic situations, there are concerns about the availability of adequate supplies and, in low-income countries, their affordability. Given those limitations of conventional drugs, and that the studies included in the current review investigated ILI, not virologically confirmed influenza, the advent of higher-quality data on alternative or additional options, such as Oscillococcinum<SUP>®</SUP>, would be of interest.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-09-25 02:52:22 +1000" MODIFIED_BY="Robert T Mathie">
<P>The two prophylaxis trials comprised a total of 327 participants; the quality of their reporting was poor and the studies may have been underpowered. The two treatment trials in which our ascribed 'primary outcome measure' was reported (patient-reported absence of symptoms at 48 hours) comprised a total of 796 participants: overall, these trials were of unclear risk of bias (GRADE Working Group: 'low quality of evidence' - <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The available body of evidence therefore does not enable robust conclusions about the impact of Oscillococcinum<SUP>® </SUP>in preventing and/or treating influenza or influenza-like illness.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Some trials of homeopathy are published in the 'grey' literature, which is not indexed in medical bibliographic databases; such was the case with several of the trials reviewed here. We have made efforts to search comprehensively and have identified and included two new trials (<LINK REF="STD-Selkova-2005a" TYPE="STUDY">Selkova 2005a</LINK>; <LINK REF="STD-Selkova-2005b" TYPE="STUDY">Selkova 2005b</LINK>), which are not indexed in the standard medical bibliographic databases. Nevertheless it remains possible that we have missed some trials, though we consider it unlikely that we have failed to identify any study of sufficient quality that would influence our findings importantly. We assessed the eligible trials rigorously for risk of bias. We identified all five original studies (six trials) as lacking clarity in some or all assessment domains. We rated no trial overall as low risk of bias and so the conclusions about trial results drawn from this review are necessarily cautious in nature.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-11-14 21:01:16 +1000" MODIFIED_BY="Robert T Mathie">
<P>Three other reviews have appraised the evidence of Oscillococcinum<SUP>® </SUP>or Oscillococcinum-like homeopathic preparations (<LINK REF="REF-Bornh_x00f6_ft-2006" TYPE="REFERENCE">Bornhöft 2006</LINK>; <LINK REF="REF-Marrari-2012" TYPE="REFERENCE">Marrari 2012</LINK>; <LINK REF="REF-Ulbricht--2011" TYPE="REFERENCE">Ulbricht 2011</LINK>). The first review cited <LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK> and <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK> as showing 'significance for homeopathy' and categorised each of those studies as having unclear external validity. The second review appraised the evidence both from the original randomised controlled trials and the earlier reviews: its findings and conclusions are broadly in line with this Cochrane Review, though it regarded the paper by <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK> as "well-designed and well-reported". The third review concluded that, given the available evidence including its high benefit/risk ratio, Oscillococcinum<SUP>®</SUP> should be assigned the classification "generally proven". None of these three reviews cited the paper by Selkova (<LINK REF="STD-Selkova-2005a" TYPE="STUDY">Selkova 2005a</LINK>; <LINK REF="STD-Selkova-2005b" TYPE="STUDY">Selkova 2005b</LINK>). The present review is less positively positioned than any of those above.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>As stated in <LINK TAG="EFFECT_MEASURES" TYPE="SECTION">Measures of treatment effect</LINK>, at a population level there would be significant social gains from at least a 5% absolute increase in the proportion of individuals achieving symptom relief at 48 hours. Our findings do not rule out the possibility that Oscillococcinum<SUP>®</SUP> could have such impact but, given the low quality of the eligible studies, the evidence is not compelling. It seems clear that Oscillococcinum<SUP>®</SUP> provides no additional benefit beyond the third day of treatment, and this is consistent with the self limiting natural course of the disease. There is no evidence of clinically important harms.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Overall, the findings from this review have been obtained from trials of low quality. Confirmatory placebo-controlled studies of high quality therefore seem warranted to study the efficacy of Oscillococcinum<SUP>®</SUP> both in prevention and treatment of influenza and influenza-like illness (ILI).</P>
<P>The existing research studies on influenza prophylaxis using Oscillococcinum<SUP>® </SUP>are very poorly reported and robust conclusions cannot be drawn from them. Nevertheless, if it were effective for prevention, Oscillococcinum<SUP>®</SUP> might be an interesting intervention. It would not suffer from the lag of several months between the identification of the epidemic strain and large-scale production of a vaccine and it might be effective against ILI which, even in an epidemic, forms the bulk of clinically diagnosed influenza. These considerations would need to be balanced against the scale and expense of the trials required to answer this question adequately, especially given the highly equivocal nature of the current data.</P>
<P>The two treatment trials, <LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK> and <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK>, yielded combined data that showed an absolute risk reduction of 7.7%; the total sample size of 796 participants provided sufficient statistical power to detect that substantial treatment effect. However, the quality of the evidence from these treatment trials is considerably less than robust, and further research is indicated. Based on the combined data from the control arms of the treatment trials by <LINK REF="STD-Ferley-1989" TYPE="STUDY">Ferley 1989</LINK> and <LINK REF="STD-Papp-1998" TYPE="STUDY">Papp 1998</LINK> (in which the frequency of improvement in the placebo group was 9%), we conducted a sample size calculation (<LINK REF="REF-Altman-1991" TYPE="REFERENCE">Altman 1991</LINK>) for patient-reported symptom relief at 48 hours as the main outcome measure, with an absolute improvement in frequency of symptom relief of 5% as the minimal clinically important benefit (see <LINK TAG="IMPLICATIONS_PRACTICE" TYPE="SECTION">Implications for practice</LINK> above), power set at 90% and a 5% level of statistical significance: the required sample is 1600 (i.e. 800 patients per group), which is twice the size of Ferley's and Papp's trials combined. Ideally, such a 'definitive' trial of Oscillococcinum<SUP>®</SUP> treatment should also plan subgroup analyses to investigate Ferley's tentative finding of a greater effect in patients under 30 years of age and in those with less severe symptoms. Due to its very large size, such a trial would obviously require substantial financial and organisational resources.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-01-14 21:52:02 +1000" MODIFIED_BY="[Empty name]">
<P>The authors are grateful to: Elizabeth Dooley, Managing Editor, Cochrane Acute Respiratory Infections (ARI) Group, for her skill and attentiveness in overseeing this review update; Sarah Thorning, Cochrane ARI Group, for undertaking the literature search updates; Phil Wiffen, UK Cochrane Centre, for general guidance in meta-analysis methods; and Maria Ximena Rojas Reyes, Collaborator Centre for the Ibero-American Cochrane Center, Pontificia Universidad Javeriana, Bogotá, Colombia, for kind assistance with the 'Summary of findings' table. We appreciate the input of individuals who refereed our first submitted manuscript: Anne Lyddiatt (Consumer referee), Edzard Ernst (External Referee), Mark Jones (Statistical Editor) and Taixiang Wu (Contact Editor).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-01-24 09:47:54 +1000" MODIFIED_BY="Liz  Dooley">
<P>All three review authors are research-active in the field of homeopathy. They were members of the International Scientific Committee for Homeopathic Investigations (ISCHI), whose membership also included two employees of Boiron (the manufacturers of Oscillococcinum<SUP>®</SUP>), and whose committee activities ceased in July 2013. Progress with the Cochrane Review on Oscillococcinum<SUP>®</SUP> was presented briefly at ISCHI meetings in 2010 and 2011. The drafting of this Cochrane Review was carried out independently of those communications and of the authors' other ongoing research activity. ISCHI has not run or sponsored any research on Oscillococcinum®.</P>
<P>Robert T Mathie: Dr Mathie is Research Development Adviser, British Homeopathic Association. He was a member of the International Scientific Committee on Homeopathic Investigations, which ceased its committee activities in July 2013.<BR/>Joyce Frye: Dr. Frye received partial salary support from Standard Homeopathic Company, which terminated June 2013 and honoraria from the International Scientific Committee on Homeopathic Investigations, which was dissolved in July 2013.<BR/>Peter Fisher: I am Expert Adviser on Complementary and Alternative Medicine to the National Institute for Health and Clinical Excellence (NICE), which may take an interest in the evidence in this review. I am Editor in Chief of an international, peer-reviewed journal dedicated to homeopathy. All payments and reimbursements for lectures have been from universities or professional or learned societies. None of these lectures has been dedicated to the subject of this review. Some meetings have been supported by grants from commercial interests, including the manufacturer of the product that is the subject of the review.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Andrew Vickers wrote the protocol and consequent text of the original review; he undertook the data analyses and, along with Claire Smith, the original data extractions.<BR/>For the 2012 update, based on amended exclusion criteria for eligible studies, Robert Mathie undertook the 'Risk of bias' assessments, data extractions and analyses and led the drafting of the review text; Joyce Frye and Peter Fisher undertook the 'Risk of bias' assessments and co-edited the review text.<BR/>For this 2014 update, Robert Mathie screened the new search results, determining that none was eligible for inclusion; Joyce Frye and Peter Fisher agreed with those primary decisions.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>This review has focused explicitly and solely on registered trademark Oscillococcinum<SUP>®</SUP>. The rationale for this focus is described in the <LINK TAG="INTERVENTION" TYPE="SECTION">Description of the intervention</LINK> and <LINK TAG="CRIT_INTERVENTIONS" TYPE="SECTION">Types of interventions</LINK> sections.</LI>
<LI>The original authors of published studies were not invited to clarify or provide missing data. See <LINK TAG="DATA_EXTRACTION" TYPE="SECTION">Data extraction and management</LINK> section.</LI>
</OL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="[Empty name]">
<P>The original review was withdrawn from <I>The Cochrane Library</I>, 2009, Issue 3 as the authors were unable to update it. This review has been updated by a new team of authors.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-01-22 14:58:30 +1000" MODIFIED_BY="Liz  Dooley">
<STUDIES MODIFIED="2012-11-14 20:54:07 +1000" MODIFIED_BY="Robert T Mathie">
<INCLUDED_STUDIES MODIFIED="2012-11-14 20:54:07 +1000" MODIFIED_BY="Robert T Mathie">
<STUDY DATA_SOURCE="PUB" ID="STD-Casanova-1984" MODIFIED="2012-03-13 15:57:12 +1000" MODIFIED_BY="Robert T Mathie" NAME="Casanova 1984" NOTES="&lt;p&gt;[volume number not given]&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 15:57:12 +1000" NOTES_MODIFIED_BY="Robert T Mathie" YEAR="1984">
<REFERENCE MODIFIED="2012-03-13 15:56:58 +1000" MODIFIED_BY="Robert T Mathie" NOTES="&lt;p&gt;Casanova P. Homeopathie, syndrome grippal et double insu. Tonus 1984:25-6&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 15:56:58 +1000" NOTES_MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casanova, Basquin, Mangenay, Pacotte, Questel [first initials not given]</AU>
<TI>Homeopathy, flu syndrome and double blinding</TI>
<TO>Homéopathie, syndrome grippal et double insu</TO>
<SO>Tonus</SO>
<YR>1984</YR>
<PG>25-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-12-13 23:08:18 +1000" MODIFIED_BY="Robert T Mathie"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casanova-1988" MODIFIED="2011-12-19 10:43:14 +1000" MODIFIED_BY="Robert T Mathie" NAME="Casanova 1988" YEAR="1992">
<REFERENCE MODIFIED="2011-12-19 10:43:14 +1000" MODIFIED_BY="Robert T Mathie" NOTES="&lt;p&gt;Casanova P. Gerard R. Bilan de 3 ann&amp;#233;es d'&amp;#233;tudes randomis&amp;#233;es multicentriques oscillococcinum/placebo. Unpublished: Oscillococcinum - rassegna della letterature internationale. Milan: Laboratiores Boiron;1992:11-6&lt;/p&gt;" NOTES_MODIFIED="2011-12-19 10:43:14 +1000" NOTES_MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Casanova P, Gerard R</AU>
<TI>Results of three years of randomised, multicentre studies on Oscillococcinum/placebo</TI>
<TO>Bilan de 3 années d'études randomisées multicentriques Oscillococcinum/placebo</TO>
<SO>Proposta Omeopatica</SO>
<YR>1988</YR>
<VL>3</VL>
<PG>14-7</PG>
<EN>Anno VI</EN>
<PB>Boiron</PB>
<CY>Milan</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferley-1989" MODIFIED="2010-11-27 00:12:22 +1000" MODIFIED_BY="Robert T Mathie" NAME="Ferley 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Ferley JP. Zmirou D. D'Adhemar D. Balducci F. A controlled evaluation of a homoeopathic preparation in the treatment of influenza-like syndromes. British Journal of Clinical Pharmacology 1989;27:329-35&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferley JP, Zmirou D, D'Adhemar D, Balducci F</AU>
<TI>A controlled evaluation of a homoeopathic preparation in the treatment of influenza-like syndromes</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1989</YR>
<VL>27</VL>
<PG>329-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89247264"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papp-1998" MODIFIED="2011-12-19 10:43:42 +1000" MODIFIED_BY="Robert T Mathie" NAME="Papp 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-12-19 10:43:42 +1000" MODIFIED_BY="Robert T Mathie" NOTES="&lt;p&gt;Papp R, Schuback G, Beck E, Burkard G, Bengel J, Lehrl S, Belon P. Oscillococcinum in patients with influenza-like syndromes: a placebo-controlled double-blind evaluation. British Homoeopathic Journal 1998;87:69-76&lt;/p&gt;" NOTES_MODIFIED="2011-12-19 10:43:42 +1000" NOTES_MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papp R, Schuback G, Beck E, Burkard G, Bengel J, Lehrl S, et al</AU>
<TI>Oscillococcinum in patients with influenza-like syndromes: a placebo-controlled double-blind evaluation</TI>
<SO>British Homoeopathic Journal</SO>
<YR>1998</YR>
<VL>87</VL>
<PG>69-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Selkova-2005a" MODIFIED="2012-11-14 20:51:05 +1000" MODIFIED_BY="Robert T Mathie" NAME="Selkova 2005a" YEAR="2005a">
<REFERENCE MODIFIED="2012-11-14 20:50:15 +1000" MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selkova EP, Semenenko TA, Gorbachev IA</AU>
<TI>Use of the medicine Oscillococcinum® for the prevention and treatment of influenza and acute respiratory viral infection</TI>
<SO>Infectionni Bolezni</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>20-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-11-14 20:51:05 +1000" MODIFIED_BY="Robert T Mathie"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Selkova-2005b" MODIFIED="2012-11-14 20:54:07 +1000" MODIFIED_BY="Robert T Mathie" NAME="Selkova 2005b" YEAR="2005b">
<REFERENCE MODIFIED="2012-11-14 20:53:50 +1000" MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Selkova EP, Semenenko TA, Gorbachev IA</AU>
<TI>Use of the medicine Oscillococcinum® for the prevention and treatment of influenza and acute respiratory viral infection</TI>
<SO>Infectionni Bolezni</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>20-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie">
<STUDY DATA_SOURCE="PUB" ID="STD-Attena-1995" MODIFIED="2011-12-19 10:44:22 +1000" MODIFIED_BY="Robert T Mathie" NAME="Attena 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-12-19 10:44:22 +1000" MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Attena F, Toscano G, Agozzino E, Del Giudice N</AU>
<TI>A randomized trial in the prevention of influenza-like syndromes by homoeopathic management</TI>
<SO>Revue d'Epidémiologie et de Santé Publique</SO>
<YR>1995</YR>
<VL>43</VL>
<PG>380-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brydak-1999" MODIFIED="2010-11-27 00:02:12 +1000" MODIFIED_BY="Robert T Mathie" NAME="Brydak 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-27 00:02:12 +1000" MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brydak LB, Denys A</AU>
<TI>The evaluation of humoral response and the clinical evaluation of a risk-group patients&#8217; state of health after administration of the homeopathic preparation Gripp-Heel during the influenza epidemic season 1993/94</TI>
<SO>International Review of Allergology and Clinical Immunology</SO>
<YR>1999</YR>
<VL>5</VL>
<PG>223&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bungetzianu-1985" NAME="Bungetzianu 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Bungetzianu G. The results obtained by the homeopathical dilution (15 CH) of an antiinfluenzal (Anti-Flu-) vaccine. IN: Proceedings of the 40th Congress of the LMHI (Lyon) 1985;40:143&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bungetzianu G</AU>
<TI>The results obtained by the homeopathical dilution (15 CH) of an antiinfluenzal (Anti-Flu) vaccine</TI>
<SO>Proceedings of the 40th Congress of the LMHI</SO>
<YR>1985</YR>
<PG>143</PG>
<CY>Lyon</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferley-1987" MODIFIED="2011-12-15 00:45:40 +1000" MODIFIED_BY="Robert T Mathie" NAME="Ferley 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-12-15 00:45:40 +1000" MODIFIED_BY="Robert T Mathie" NOTES="&lt;p&gt;The paper was read in translation.&lt;/p&gt;" NOTES_MODIFIED="2011-12-15 00:45:40 +1000" NOTES_MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferley JP, Poutignat N, Azzopardi Y, Charrel M, Zmirou D</AU>
<TI>Outpatient evaluation of the effect of a homeopathic complex remedy in the prevention of flu and flu-like syndromes</TI>
<TO>Evaluation en médecine ambulatoire de l'activité d'un complexe homéopathique dans la prévention de la grippe et des syndromes grippaux</TO>
<SO>Immunologie Médicale</SO>
<YR>1987</YR>
<VL>20</VL>
<PG>22-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heilmann-1992" NAME="Heilmann 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;The paper was read in translation.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heilmann A</AU>
<TI>An injectable combined medication (Engystol N) as a prevention against the flu</TI>
<TO>Ein injizierbares Kombinationspräparat (Engystol N) als Prophylaktikum des grippalen Infekts</TO>
<SO>Biologische Medizin</SO>
<YR>1992</YR>
<VL>21</VL>
<PG>225-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hourst-1982" MODIFIED="2011-12-15 03:39:37 +1000" MODIFIED_BY="Robert T Mathie" NAME="Hourst 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-12-15 03:39:37 +1000" MODIFIED_BY="Robert T Mathie" NOTES="&lt;p&gt;Unpublished. The paper was read in translation.&lt;/p&gt;" NOTES_MODIFIED="2011-12-15 03:39:37 +1000" NOTES_MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Hourst P</AU>
<TI>Tentative appreciation of homeopathy's effectiveness</TI>
<TO>Tentative j'appréciation de l'effacacité de l'homéopathie</TO>
<SO>Unpublished Dissertation, Pitie-Salpetrière: Universite Pierre et Marie Curie</SO>
<YR>1982</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapitskaya-2010" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" NAME="Lapitskaya 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapitskaya A, Selkova E, Lytkina I, Grenkova T</AU>
<TI>Homeopathic medicine Oscillococcinum and influenza vaccine in preventing influenza-like illnesses in children</TI>
<SO>Acta Pædiatrica</SO>
<YR>2010</YR>
<VL>99</VL>
<NO>Suppl 462</NO>
<PG>86-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lecocq-1985" NAME="Lecocq 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;The paper was read in translation&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lecocq P</AU>
<TI>Therapeutic means to treat flu</TI>
<TO>Les voies therapeutiques des syndromes grippaux</TO>
<SO>Cahiers de Biothérapie</SO>
<YR>1985</YR>
<VL>87</VL>
<PG>65-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewith-1989" NAME="Lewith 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Lewith G, Brown PK, Tyrell DA. Controlled study of the effects of a homoeopathic dilution of influenza vaccine on antibody titres in man. Complementary Medical Research 1989;3:22-4&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewith G, Brown PK, Tyrell DA</AU>
<TI>Controlled study of the effects of a homoeopathic dilution of influenza vaccine on antibody titres in man</TI>
<SO>Complementary Medical Research</SO>
<YR>1989</YR>
<VL>3</VL>
<PG>22-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masciello-1985" MODIFIED="2011-12-19 10:45:29 +1000" MODIFIED_BY="Robert T Mathie" NAME="Masciello 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-12-19 10:45:29 +1000" MODIFIED_BY="Robert T Mathie" NOTES="&lt;p&gt;Unpublished. The paper was read in translation and no English title is available&lt;/p&gt;" NOTES_MODIFIED="2011-12-19 10:45:29 +1000" NOTES_MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Masciello E, Felisi E</AU>
<TI>Dilutions of material, with a high percentage of DNA and RNA, in the presentation of viral epidemics</TI>
<TO>Dilutions de matériel, à pourcentage élevé de ADN et ARN, dans la prévention des viroses epidemiques</TO>
<SO>Proceedings of the 40th Congress of the Liga Medicorum Homoeopathica Internationalis, Lyon</SO>
<YR>1985</YR>
<PG>271-4</PG>
<CY>Lyon</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nollevaux-1990" MODIFIED="2011-12-19 10:45:56 +1000" MODIFIED_BY="Robert T Mathie" NAME="Nollevaux 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-12-19 10:45:56 +1000" MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Nollevaux MA, Danhier Ph, Fagard H</AU>
<TI>Double-blind clinical observations versus placebo of Mucococcinum 200K in the preventive treatment of flu-like symptoms</TI>
<TO>Observations cliniques en double aveugle contre placebo, de Mucococcinum 200K dans le traitement préventif des états grippaux</TO>
<SO>Unpublished</SO>
<YR>1990</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabe-2004" NAME="Rabe 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabe A, Weiser M, Klein P</AU>
<TI>Effectiveness and tolerability of a homoeopathic remedy compared with conventional therapy for mild viral infections</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>9</NO>
<PG>827-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rottey-1995" MODIFIED="2011-12-19 10:46:51 +1000" MODIFIED_BY="Robert T Mathie" NAME="Rottey 1995" YEAR="1996">
<REFERENCE MODIFIED="2011-12-19 10:46:51 +1000" MODIFIED_BY="Robert T Mathie" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rottey EED, Verleye GB, Liagre RLP</AU>
<TI>The effects of a homeopathic remedy made of micro-organisms in the prevention of flu. A randomised double-blind trial in GP practices</TI>
<TO>Het effect van een homeopathische bereiding van micro-organismen bij de preventie van griepsymptomen. Een gerandomiseerd dubbel-blind onderzoek in de huisartspraktijk</TO>
<SO>Tijdschrift voor Integrale Geneeskunde</SO>
<YR>1995</YR>
<VL>11</VL>
<PG>54-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2012-07-18 21:45:07 +1000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-01-22 14:58:30 +1000" MODIFIED_BY="Liz  Dooley">
<ADDITIONAL_REFERENCES MODIFIED="2015-01-14 22:01:23 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1991" MODIFIED="2012-09-27 07:13:04 +1000" MODIFIED_BY="Robert T Mathie" NAME="Altman 1991" TYPE="BOOK_SECTION">
<AU>Altman DG</AU>
<TI>Sample size, hypothesis tests and power</TI>
<SO>Practical Statistics for Medical Research</SO>
<YR>1991</YR>
<PG>455-60</PG>
<PB>Chapman &amp; Hall</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bellavite-2007" MODIFIED="2012-07-31 12:18:42 +1000" MODIFIED_BY="Robert T Mathie" NAME="Bellavite 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bellavite P, Ortolani R, Pontarollo F, Pitari G, Conforti A</AU>
<TI>Immunology and homeopathy. 5. The rationale of the 'Simile'</TI>
<SO>Evidence-based Complementary and Alternative Medicine: eCAM</SO>
<YR>2007</YR>
<VL>4</VL>
<PG>149-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bornh_x00f6_ft-2006" MODIFIED="2011-12-19 10:47:57 +1000" MODIFIED_BY="Robert T Mathie" NAME="Bornhöft 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bornhöft G, Wolf U, von Ammon K, Righetti M, Maxion-Bergemann S, Baumgartner S, et al</AU>
<TI>Effectiveness, safety and cost-effectiveness of homeopathy in general practice - summarized health technology assessment</TI>
<SO>Forschende Komplementarmedizin</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>Suppl 2</NO>
<PG>19-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Call-2005" MODIFIED="2012-03-13 16:00:18 +1000" MODIFIED_BY="[Empty name]" NAME="Call 2005" TYPE="JOURNAL_ARTICLE">
<AU>Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP</AU>
<TI>Does this patient have influenza?</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>8</NO>
<PG>987-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDCP-2010" MODIFIED="2012-07-31 12:19:03 +1000" MODIFIED_BY="Robert T Mathie" NAME="CDCP 2010" TYPE="OTHER">
<AU>Centers for Disease Control and Prevention</AU>
<TI>Key facts about avian influenza (bird flu) and highly pathogenic avian influenza A (H5N1) virus, 2010</TI>
<SO>http://www.cdc.gov/flu/avian/gen-info/facts.htm (accessed 18 July 2012)</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CDCP-2011" MODIFIED="2012-07-31 12:19:21 +1000" MODIFIED_BY="Robert T Mathie" NAME="CDCP 2011" TYPE="OTHER">
<AU>Centers for Disease Control and Prevention</AU>
<TI>Seasonal influenza (flu), 7 November 2011</TI>
<SO>http://www.cdc.gov/flu/weekly/weeklyarchives2009-2010/09-10summary.htm (accessed 18 July 2012)</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clausen-2011" MODIFIED="2011-12-13 23:12:11 +1000" MODIFIED_BY="Robert T Mathie" NAME="Clausen 2011" TYPE="JOURNAL_ARTICLE">
<AU>Clausen J, van Wijk R, Albrecht H</AU>
<TI>Review of the use of high potencies in basic research on homeopathy</TI>
<SO>Homeopathy</SO>
<YR>2011</YR>
<VL>100</VL>
<PG>288-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Demangeat-2004" MODIFIED="2012-07-23 14:48:59 +1000" MODIFIED_BY="Robert T Mathie" NAME="Demangeat 2004" TYPE="JOURNAL_ARTICLE">
<AU>Demangeat J-L, Gries P, Poitevin B, Droesbeke J-J, Zahaf T, Maton F, et al</AU>
<TI>Low-field NMR water proton longitudinal relaxation in ultrahighly diluted aqueous solutions of silica-lactose prepared in glass material for pharmaceutical use</TI>
<SO>Applied Magnetic Resonance</SO>
<YR>2004</YR>
<VL>26</VL>
<PG>465-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Demangeat-2009" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" NAME="Demangeat 2009" TYPE="JOURNAL_ARTICLE">
<AU>Demangeat J-L</AU>
<TI>NMR water proton relaxation in unheated and heated ultrahigh aqueous dilutions of histamine: evidence for an air-dependent supramolecular organization of water</TI>
<SO>Journal of Molecular Liquids</SO>
<YR>2009</YR>
<VL>144</VL>
<PG>32&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eizayaga-2011" MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" NAME="Eizayaga 2011" TYPE="OTHER">
<AU>Eizayaga FX, Aguejouf O, Desplat V, Doutremepuich C</AU>
<TI>Beneficial effect of ultra-low-dose aspirin in platelet activity alterations and haemorrhage observed in experimental portal hypertension</TI>
<SO>Thrombosis</SO>
<YR>2011 Nov 14 [Epub ahead of publication]</YR>
<IDENTIFIERS MODIFIED="2015-01-14 21:07:13 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-01-14 21:07:13 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1155/2012/430460"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Endler-2010" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" NAME="Endler 2010" TYPE="JOURNAL_ARTICLE">
<AU>Endler PCK, Thieves K, Reich C, Matthiessen P, Bonamin L, Scherr C, et al</AU>
<TI>Repetitions of fundamental research models for homeopathically prepared dilutions beyond 10<SUP>-23</SUP>
</TI>
<SO>Homeopathy</SO>
<YR>2010</YR>
<VL>99</VL>
<PG>25-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HPUSA-2012" MODIFIED="2012-08-21 00:50:03 +1000" MODIFIED_BY="Robert T Mathie" NAME="HPUSA 2012" TYPE="OTHER">
<AU>Homeopathic Pharmacopoeia Convention of the United States</AU>
<TI>Monograph: Anas barbariae hepatis et cordis extractum</TI>
<SO>Southeastern, PA</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2009a" MODIFIED="2012-10-31 09:08:55 +1000" MODIFIED_BY="Robert T Mathie" NAME="Jefferson 2009a" TYPE="JOURNAL_ARTICLE">
<AU>Jefferson T, Jones MA, Doshi P, Del Mar CB, Dooley L, Foxlee R</AU>
<TI>Neuraminidase inhibitors for preventing and treating influenza in healthy adults</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>b5106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2009b" MODIFIED="2012-10-31 09:09:23 +1000" MODIFIED_BY="Robert T Mathie" NAME="Jefferson 2009b" TYPE="COCHRANE_REVIEW">
<AU>Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D</AU>
<TI>Amantadine and rimantadine for influenza A in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-10-31 09:09:23 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-31 09:09:15 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001169.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2014" MODIFIED="2015-01-14 22:01:23 +1000" MODIFIED_BY="[Empty name]" NAME="Jefferson 2014" TYPE="COCHRANE_REVIEW">
<AU>Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, et al</AU>
<TI>Neuraminidase inhibitors for preventing and treating influenza in adults and children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-10-14 09:14:27 +1000" MODIFIED_BY="Liz  Dooley">
<IDENTIFIER MODIFIED="2014-10-14 09:14:27 +1000" MODIFIED_BY="Liz  Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD008965.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kayne-2006" MODIFIED="2012-02-09 03:59:45 +1000" MODIFIED_BY="[Empty name]" NAME="Kayne 2006" TYPE="BOOK">
<AU>Kayne SB</AU>
<SO>Homoeopathic Pharmacy</SO>
<YR>2006</YR>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Linde-1997" MODIFIED="2011-12-19 11:14:37 +1000" MODIFIED_BY="[Empty name]" NAME="Linde 1997" TYPE="JOURNAL_ARTICLE">
<AU>Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges LV</AU>
<TI>Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>834-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97456644"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marrari-2012" MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" NAME="Marrari 2012" TYPE="JOURNAL_ARTICLE">
<AU>Marrari LA, Terzan L, Chaufferin G</AU>
<TI>Oscillococcinum for influenza treatment</TI>
<SO>Annali dell'Istituto Superiore di Sanità</SO>
<YR>2012</YR>
<VL>48</VL>
<PG>105&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osterholm-2011" MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" NAME="Osterholm 2011" TYPE="OTHER">
<AU>Osterholm MT, Kelley NS, Sommer A, Belongia EA</AU>
<TI>Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2011 Oct 25 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-10-12 12:36:34 +1000" MODIFIED_BY="Liz  Dooley" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>RevIew Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rey-2003" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" NAME="Rey 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rey L</AU>
<TI>Thermoluminescence of ultra-high dilutions of lithium chloride and sodium chloride</TI>
<SO>Physica (A)</SO>
<YR>2003</YR>
<VL>323</VL>
<PG>67-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ste-Laudy-2009" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" NAME="Ste Laudy 2009" TYPE="JOURNAL_ARTICLE">
<AU>Laudy J, Belon P</AU>
<TI>Inhibition of basophil activation by histamine: a sensitive and reproducible model for study of biological activity of high dilutions</TI>
<SO>Homeopathy</SO>
<YR>2009</YR>
<VL>98</VL>
<PG>186&#8211;97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swayne-2000" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" NAME="Swayne 2000" TYPE="BOOK">
<AU>Swayne J</AU>
<SO>International Dictionary of Homeopathy</SO>
<YR>2000</YR>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ulbricht--2011" MODIFIED="2012-01-31 00:43:35 +1000" MODIFIED_BY="Robert T Mathie" NAME="Ulbricht  2011" TYPE="JOURNAL_ARTICLE">
<AU>Ulbricht C, Chao W, Clark A, Conquer J, Cook D, Cormier T, et al</AU>
<TI>Oscillococcinum (Anas barbariae hepatis et cordis extractum 200CK HPUS). An evidence-based systematic review by the Natural Standard Research Collaboration</TI>
<SO>Alternative and Complementary Therapies</SO>
<YR>2011</YR>
<VL>17</VL>
<PG>41-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Wijk-2006" MODIFIED="2011-12-19 10:57:05 +1000" MODIFIED_BY="Robert T Mathie" NAME="Van Wijk 2006" TYPE="JOURNAL_ARTICLE">
<AU>Van Wijk R, Bosman S, van Wijk EP</AU>
<TI>Thermoluminescence in ultra-high dilution research</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>437&#8211;43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2012" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" NAME="Wang 2012" TYPE="COCHRANE_REVIEW">
<AU>Wang K, Shun-Shin M, Gill P, Perera R, Harnden A</AU>
<TI>Neuraminidase inhibitors for preventing and treating influenza in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-08-20 23:50:09 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-20 23:50:09 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002744.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Watanabe-2011" MODIFIED="2011-12-19 10:57:41 +1000" MODIFIED_BY="Robert T Mathie" NAME="Watanabe 2011" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe Y, Ibrahim MS, Ellakany HF, Abd El-Hamid HS, Ikuta K</AU>
<TI>Genetic diversification of H5N1 highly pathogenic avian influenza A virus during replication in wild ducks</TI>
<SO>Journal of General Virology</SO>
<YR>2011</YR>
<VL>92</VL>
<PG>2105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2006" MODIFIED="2012-07-31 12:19:50 +1000" MODIFIED_BY="Robert T Mathie" NAME="WHO 2006" TYPE="OTHER">
<AU>World Health Organization: Regional Office for Europe's Health Evidence Network (HEN)</AU>
<TI>How effective would antiviral vaccination and antiviral drug prevention and treatment strategies be for reducing the impact of the next influenza pandemic? 2006</TI>
<SO>http://www.euro.who.int/__data/assets/pdf_file/0003/74658/E88034.pdf (accessed 18 July 2012)</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2009" MODIFIED="2012-07-31 12:20:04 +1000" MODIFIED_BY="Robert T Mathie" NAME="WHO 2009" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Influenza (Seasonal); Fact Sheet No. 211, 2009</TI>
<SO>http://www.who.int/mediacentre/factsheets/fs211/en/ (accessed 18 July 2012)</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Witt-2007" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" NAME="Witt 2007" TYPE="JOURNAL_ARTICLE">
<AU>Witt CM, Bluth M, Albrecht H, Weißhuhn T, Baumgartner S, Willich SN</AU>
<TI>The in vitro evidence for an effect of high homeopathic potencies &#8211; a systematic review of the literature</TI>
<SO>Complementary Therapies in Medicine</SO>
<YR>2007</YR>
<VL>15</VL>
<PG>128&#8211;38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woo-2011" MODIFIED="2011-12-19 10:58:31 +1000" MODIFIED_BY="Robert T Mathie" NAME="Woo 2011" TYPE="JOURNAL_ARTICLE">
<AU>Woo GH, Kim HY, Bae YC, Jean YH, Bak EJ, Kim MJ, et al</AU>
<TI>Comparative histopathological characteristics of highly pathogenic avian influenza (HPAI) in chickens and domestic ducks in 2008 Korea</TI>
<SO>Histology and Histopathology</SO>
<YR>2011</YR>
<VL>26</VL>
<PG>167-75</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-01-22 14:58:30 +1000" MODIFIED_BY="Liz  Dooley">
<REFERENCE ID="REF-Mathie-2012" MODIFIED="2014-10-12 12:18:22 +1000" MODIFIED_BY="Liz  Dooley" NAME="Mathie 2012" TYPE="COCHRANE_REVIEW">
<AU>Mathie RT, Frye J, Fisher P</AU>
<TI>Homeopathic Oscillococcinum® for preventing and treating influenza and influenza-like illness</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2014-10-12 12:13:04 +1000" MODIFIED_BY="Liz  Dooley">
<IDENTIFIER MODIFIED="2014-10-12 12:13:04 +1000" MODIFIED_BY="Liz  Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD001957.pub5"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vickers-1998" MODIFIED="2015-01-22 14:58:30 +1000" MODIFIED_BY="Liz  Dooley" NAME="Vickers 1998" TYPE="COCHRANE_PROTOCOL">
<AU>Vickers A, Smith C</AU>
<TI>Homeopathic Oscillococcinum for preventing and treating influenza and influenza-like syndromes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-01-22 14:56:23 +1000" MODIFIED_BY="Liz  Dooley">
<IDENTIFIER MODIFIED="2015-01-22 14:56:23 +1000" MODIFIED_BY="Liz  Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD001957"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vickers-2000" MODIFIED="2015-01-14 21:55:01 +1000" MODIFIED_BY="[Empty name]" NAME="Vickers 2000" TYPE="COCHRANE_REVIEW">
<AU>Vickers A, Smith C</AU>
<TI>Homeopathic Oscillococcinum for preventing and treating influenza and influenza-like syndromes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-12-19 10:32:47 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-19 10:32:47 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001957.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vickers-2004" MODIFIED="2015-01-14 21:55:06 +1000" MODIFIED_BY="[Empty name]" NAME="Vickers 2004" TYPE="COCHRANE_REVIEW">
<AU>Vickers A, Smith C</AU>
<TI>Homeopathic Oscillococcinum for preventing and treating influenza and influenza-like syndromes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001957.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vickers-2006" MODIFIED="2015-01-14 21:55:14 +1000" MODIFIED_BY="[Empty name]" NAME="Vickers 2006" TYPE="COCHRANE_REVIEW">
<AU>Vickers A, Smith C</AU>
<TI>Homeopathic Oscillococcinum for preventing and treating influenza and influenza-like syndromes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001957.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casanova-1984">
<CHAR_METHODS MODIFIED="2012-10-30 20:22:06 +1000" MODIFIED_BY="Robert T Mathie">
<P>Randomised, placebo-controlled trial of Oscillococcinum<SUP>®</SUP> in the treatment of influenza-like illness</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>100 participants with influenza-like illness onset less than 48 hours previously<BR/>No details of method of recruitment or exclusion criteria<BR/>Average age of Oscillococcinum/placebo groups: 42/41 years<BR/>Males:females in Oscillococcinum/placebo groups: 19:31/26:24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-30 20:22:13 +1000" MODIFIED_BY="Robert T Mathie">
<P>Oscillococcinum<SUP>®</SUP>, 4 doses in over 2 days at 6-hour intervals</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-30 20:22:14 +1000" MODIFIED_BY="Robert T Mathie">
<P>Participant global assessment of success; presence of chills, aches, rhinitis, night cough, day cough, fever at day 8</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-30 20:22:29 +1000" MODIFIED_BY="Robert T Mathie">
<P>Reported in what appears to be a general medical magazine: very few experimental details given</P>
<P>Research setting: France (unspecified location)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casanova-1988">
<CHAR_METHODS MODIFIED="2012-10-30 20:22:32 +1000" MODIFIED_BY="Robert T Mathie">
<P>Randomised, placebo-controlled trial of Oscillococcinum<SUP>®</SUP> in the treatment of influenza</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>300 participants complaining of influenza<BR/>No details of inclusion or exclusion criteria<BR/>Average age of Oscillococcinum/placebo groups: 44/38<BR/>Males:females in Oscillococcinum/placebo: 61:89/56:94</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-30 20:22:34 +1000" MODIFIED_BY="Robert T Mathie">
<P>Oscillococcinum<SUP>®</SUP> twice a day for 3 to 4 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-30 20:22:35 +1000" MODIFIED_BY="Robert T Mathie">
<P>Temperature recorded twice a day for 4 days (data for evening of second day used for continuous outcome); presence of chills, aches at day 4</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-30 20:22:38 +1000" MODIFIED_BY="Robert T Mathie">
<P>Inconsistency between text and Table 3: the data for day 4 in the table appear to have been transposed; the text values were selected</P>
<P>Research setting: France (unspecified location)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferley-1989">
<CHAR_METHODS MODIFIED="2012-10-30 20:22:43 +1000" MODIFIED_BY="Robert T Mathie">
<P>Randomised, placebo-controlled trial of Oscillococcinum<SUP>®</SUP> in the treatment of influenza-like illness</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>487 participants presenting in primary care with a complaint of influenza-like illness<BR/>Inclusion criteria: age older than 12 years; rectal temperature above 38 °C and at least 2 of headache, stiffness, lumbar and articular pain, shivers<BR/>Exclusion criteria: duration more than 24 hours; immune deficiency; local infection; immunisation against influenza; depression; immunostimulant treatment<BR/>Average age of Oscillococcinum/placebo groups: 34/35<BR/>Males:females in Oscillococcinum/placebo groups: 93:127/97:129<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie">
<P>Oscillococcinum<SUP>®</SUP> twice a day for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure (patient-assessed): proportion of patients who recovered (defined as rectal temperature below 37.5 °C and complete resolution of all 5 symptoms) within 48 hours of treatment. Number of days to recovery; number of days to return to work; use of medication for pain or fever; use of medication for cough or sore throat; use of antibiotic medication; patient judgement of effectiveness of treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Use of medication calculated from percentages given in text. Some minor inconsistencies between figures suggest a small amount of missing data</P>
<P>Specific outcomes (temperature, symptoms including cough, coryza and fatigue) not reported <I>per se</I>
</P>
<P>Research setting: general practices in Rhône-Alpes region, France</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Papp-1998">
<CHAR_METHODS MODIFIED="2012-10-30 20:22:58 +1000" MODIFIED_BY="Robert T Mathie">
<P>Randomised, placebo-controlled trial of Oscillococcinum<SUP>®</SUP> in the treatment of influenza-like illness</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>372 participants recruited in primary care or by internal medicine specialists<BR/>Inclusion criteria: rectal temperature above 38 °C; muscle pain or headache; one of shivering, cough, spinal pain, nasal irritation, malaise, thoracic pain, periarticular pain<BR/>Exclusion criteria: duration more than 24 hours; immune deficiency; local infection; immunisation against influenza; medical need for medication; immunostimulant or immunosuppressive treatment</P>
<P>Use of analgesics, antibiotics or anti-influenza agents in the first 48 hours was a post-randomisation exclusion criterion<BR/>Average age of Oscillococcinum/placebo groups: 35/35<BR/>Males:females in Oscillococcinum/placebo groups: 95:93/96:88</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-30 20:23:25 +1000" MODIFIED_BY="Robert T Mathie">
<P>Oscillococcinum<SUP>®</SUP> 3 times a day for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-30 20:23:29 +1000" MODIFIED_BY="Robert T Mathie">
<P>Whether patients' condition improved after 48 hours (physician-assessed; authors' primary outcome); whether absence of symptoms after 48 hours (physician-assessed); time to recovery (patient-assessed; authors' primary outcome); use of concomitant medication during trial; total symptoms score; time to return to work; temperature and presence of aches, headache, shivers, back or side pain, joint pain, spinal pain, cough, rhinitis, sore throat on evening of day 2; fever calculated from temperature using normal distribution</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<P>Some outcomes not clearly reported, including mean time to recovery or return to work. Not clear which data were analysed to obtain P value = 0.023: was it date of elimination of symptoms (though mean date per group is not provided in the main text) or presence of 'milder symptoms' at 48 hours (abstract)? Both options seem to reflect our stated primary outcome</P>
<P>Physician-assessed absence of patients' symptoms at 48 hours is also emphasised by Papp (P value = 0.0028). (This outcome measure is analogous to the primary outcome in the Ferley trial (though patient-assessed in Ferley's case)). Patient-assessed absence of symptoms at 48 hours in the Papp trial may be deduced from Figure 2 of their paper</P>
<P>At 48 hours, improvement was reported by a total of 146/167 (87%) patients in the homeopathy group, compared with 136/167 (81%) in the placebo group (Table 2; statistical analysis not presented)</P>
<P>Due to the above confusion, and to approximate, as closely as possible, the main outcome measure used by the previous authors of this review, we present 'patient-assessed absence of symptoms at 48 hours' as the main outcome measure. Physician-assessed absence of symptoms and physician-assessed improvement at 48 hours are also presented (secondary outcome measures; Papp trial)</P>
<P>Research setting: general or specialist practices, Germany</P>
<P>Principal author (P Belon): employee of Boiron, the manufacturers of Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-14 20:58:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Selkova-2005a">
<CHAR_METHODS MODIFIED="2015-01-14 20:58:35 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial of Oscillococcinum<SUP>®</SUP> in the prevention of influenza-like illness</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-14 21:14:11 +1000" MODIFIED_BY="Robert T Mathie">
<P>100 professional staff (average age, 50 years approximately) in outpatient health clinic, Moscow, Russia; those with influenza-like symptoms in previous 2 days or have family contact/s displaying influenza-like symptoms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-14 21:12:25 +1000" MODIFIED_BY="Robert T Mathie">
<P>Oscillococcinum<SUP>®</SUP>, prophylactically, once per week for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-14 21:08:08 +1000" MODIFIED_BY="Robert T Mathie">
<P>Number of participants who fell ill with influenza symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-14 21:08:31 +1000" MODIFIED_BY="Robert T Mathie">
<P>Methodological details for each study are scantily described, but the tabulations of key results for each are clearly presented</P>
<P>Research setting: outpatient health clinic, Moscow, Russia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-14 20:59:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Selkova-2005b">
<CHAR_METHODS MODIFIED="2015-01-14 20:58:58 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled trial of Oscillococcinum<SUP>®</SUP> in the prevention of influenza-like illness</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-14 20:59:01 +1000" MODIFIED_BY="[Empty name]">
<P>227 students (aged 16 to 22 years), at medical school, Kalouga, Russia; not vaccinated against influenza</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-14 21:12:45 +1000" MODIFIED_BY="Robert T Mathie">
<P>Oscillococcinum<SUP>®</SUP>, prophylactically, once per week for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-14 21:10:33 +1000" MODIFIED_BY="Robert T Mathie">
<P>Number of participants who fell ill with influenza symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-14 21:10:55 +1000" MODIFIED_BY="Robert T Mathie">
<P>Methodological details for each study are scantily described, but the tabulations of key results for each are clearly presented</P>
<P>Research setting: Medical School, Kalouga, Russia</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-10-20 01:13:32 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Attena-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-20 01:13:32 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-20 01:13:33 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Brydak-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-20 01:13:33 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-30 02:14:04 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Bungetzianu-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-30 02:14:04 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-20 01:13:22 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Ferley-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-20 01:13:22 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-20 01:13:49 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Heilmann-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-20 01:13:49 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-20 01:13:51 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Hourst-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-20 01:13:51 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Lapitskaya-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-30 02:12:12 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Lecocq-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-30 02:12:12 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-30 02:12:25 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Lewith-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-30 02:12:25 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Masciello-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not placebo-controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-30 02:13:32 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Nollevaux-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-30 02:13:32 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-30 02:13:42 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Rabe-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-30 02:13:42 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-20 01:14:00 +1000" MODIFIED_BY="Robert T Mathie" STUDY_ID="STD-Rottey-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-20 01:14:00 +1000" MODIFIED_BY="Robert T Mathie">
<P>Not Oscillococcinum<SUP>®</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-07-18 21:45:07 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-11-14 21:11:59 +1000" MODIFIED_BY="Robert T Mathie">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-11-14 21:11:23 +1000" MODIFIED_BY="Robert T Mathie" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-01 01:07:29 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1984">
<DESCRIPTION>
<P>No statement about randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 21:04:42 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1988">
<DESCRIPTION>
<P>No description of randomisation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 21:06:21 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Ferley-1989">
<DESCRIPTION>
<P>No information on actual randomisation method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 21:07:12 +1000" MODIFIED_BY="Robert T Mathie" RESULT="YES" STUDY_ID="STD-Papp-1998">
<DESCRIPTION>
<P>Adequately described randomisation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 21:09:11 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005a">
<DESCRIPTION>
<P>No information on actual randomisation method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 21:11:23 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005b">
<DESCRIPTION>
<P>No information on actual randomisation method. The description "two similar groups...were randomly constituted" is equivocal</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-11-14 21:11:34 +1000" MODIFIED_BY="Robert T Mathie" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-01 01:07:34 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1984">
<DESCRIPTION>
<P>No description of allocation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 21:04:57 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1988">
<DESCRIPTION>
<P>No description of allocation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 21:06:27 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Ferley-1989">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 21:07:18 +1000" MODIFIED_BY="Robert T Mathie" RESULT="YES" STUDY_ID="STD-Papp-1998">
<DESCRIPTION>
<P>Adequately described allocation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 21:09:18 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005a">
<DESCRIPTION>
<P>No description of allocation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 21:11:34 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005b">
<DESCRIPTION>
<P>No description of allocation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-11-14 21:11:46 +1000" MODIFIED_BY="Robert T Mathie" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-01 01:07:40 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1984">
<DESCRIPTION>
<P>No description of blinding procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-18 21:05:32 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1988">
<DESCRIPTION>
<P>No description of blinding procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-18 21:06:53 +1000" MODIFIED_BY="Robert T Mathie" RESULT="YES" STUDY_ID="STD-Ferley-1989">
<DESCRIPTION>
<P>Identical presentation of active drug and placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-18 21:07:48 +1000" MODIFIED_BY="Robert T Mathie" RESULT="YES" STUDY_ID="STD-Papp-1998">
<DESCRIPTION>
<P>Identical presentation of active drug and placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-14 21:09:28 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005a">
<DESCRIPTION>
<P>No description of blinding procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-11-14 21:11:46 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005b">
<DESCRIPTION>
<P>No description of blinding procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-11-14 21:11:48 +1000" MODIFIED_BY="Robert T Mathie" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-01 01:07:46 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1984">
<DESCRIPTION>
<P>No description of blinding procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-18 21:05:39 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1988">
<DESCRIPTION>
<P>No description of blinding procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-18 21:06:58 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Ferley-1989">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-18 21:07:54 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Papp-1998">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-14 21:09:29 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005a">
<DESCRIPTION>
<P>No description of blinding procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-11-14 21:11:48 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005b">
<DESCRIPTION>
<P>No description of blinding procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-07-23 15:01:00 +1000" MODIFIED_BY="Robert T Mathie" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-11-14 21:11:58 +1000" MODIFIED_BY="Robert T Mathie" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-01 01:07:52 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1984">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-18 21:05:05 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1988">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-18 21:06:33 +1000" MODIFIED_BY="Robert T Mathie" RESULT="YES" STUDY_ID="STD-Ferley-1989">
<DESCRIPTION>
<P>Low rate of attrition (and similar rate per group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Papp-1998">
<DESCRIPTION>
<P>Moderately high overall rate of attrition (approximately 10%); numbers stated in Methods do not reconcile with those in Results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-14 21:09:40 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005a">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-11-14 21:11:58 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005b">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-11-14 21:11:58 +1000" MODIFIED_BY="Robert T Mathie" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 16:44:02 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1984">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 21:05:15 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1988">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 21:06:40 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Ferley-1989">
<DESCRIPTION>
<P>Specific outcomes not reported: temperature, symptoms including cough, coryza and fatigue</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Papp-1998">
<DESCRIPTION>
<P>Lack of clarity regarding several outcomes &#8211; see Notes above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 21:09:41 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005a">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 21:11:58 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005b">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-11-14 21:11:59 +1000" MODIFIED_BY="Robert T Mathie" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 16:44:14 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1984">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 21:05:27 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Casanova-1988">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="Robert T Mathie" RESULT="YES" STUDY_ID="STD-Ferley-1989">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias (e.g. baseline imbalance)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 21:07:39 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Papp-1998">
<DESCRIPTION>
<P>Insufficient information provided; statistical presentation unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 21:09:42 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005a">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-14 21:11:59 +1000" MODIFIED_BY="Robert T Mathie" RESULT="UNKNOWN" STUDY_ID="STD-Selkova-2005b">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-01-14 21:21:50 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-09-23 01:55:11 +1000" MODIFIED_BY="Robert T Mathie">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Oscillococcinum</B>
<SUP>®</SUP>
<B> compared with placebo for treatment of influenza</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patients/sample: </B>participants aged over 12 years, with influenza-like illness</P>
<P>
<B>Settings: </B>general or specialist practices, France and Germany<BR/>
<B>Intervention: </B>Oscillococcinum<SUP>®</SUP> twice a day for 5 days; Oscillococcinum<SUP>®</SUP> 3 times a day for 3 days</P>
<P>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Oscillococcinum<SUP>®</SUP>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Absence of symptoms at 48 hours - patient assessment</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>90 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>167 per 1000</B>
<BR/>(114 to 245)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>RR 1.86 (1.27 to 2.73)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>796 (2 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>The assumed risk is taken as that of the patients in the placebo groups of the two relevant trials. In the absence of information from other sources, calculations for low-, medium- and high-risk populations have not been calculated.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-12-18 03:58:37 +1000" MODIFIED_BY="Robert T Mathie"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-01-23 02:12:41 +1000" MODIFIED_BY="Robert T Mathie">
<COMPARISON ID="CMP-001" MODIFIED="2013-01-23 02:11:37 +1000" MODIFIED_BY="Robert T Mathie" NO="1">
<NAME>Prevention: Oscillococcinum versus placebo</NAME>
<DICH_OUTCOME CHI2="1.4908520839563142" CI_END="1.337592874390826" CI_START="0.17012234201218723" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.47702665800789446" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="44" I2="32.92426453560214" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.12632394653260026" LOG_CI_START="-0.7692386471432467" LOG_EFFECT_SIZE="-0.3214573503053233" METHOD="MH" MODIFIED="2013-01-23 02:11:37 +1000" MODIFIED_BY="Robert T Mathie" NO="1" P_CHI2="0.2220846563184592" P_Q="1.0" P_Z="0.15941643304387382" Q="0.0" RANDOM="YES" SCALE="134.01" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2897988455469948" TOTALS="YES" TOTAL_1="160" TOTAL_2="167" WEIGHT="100.0" Z="1.4070369477538875">
<NAME>Occurrence of influenza-like illness</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oscillococcinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3346052970893525" CI_START="0.020813477841245254" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.12535284424629042" LOG_CI_START="-1.6816553450135776" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2012-11-14 20:55:30 +1000" MODIFIED_BY="Robert T Mathie" ORDER="38" O_E="0.0" SE="1.0614455552060438" STUDY_ID="STD-Selkova-2005a" TOTAL_1="50" TOTAL_2="50" VAR="1.1266666666666667" WEIGHT="19.537144563750356"/>
<DICH_DATA CI_END="0.9715742541170964" CI_START="0.39029098835566245" EFFECT_SIZE="0.6157894736842106" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="38" LOG_CI_END="-0.01252400214502851" LOG_CI_START="-0.408611476268306" LOG_EFFECT_SIZE="-0.2105677392066673" MODIFIED="2012-11-14 20:55:57 +1000" MODIFIED_BY="Robert T Mathie" ORDER="39" O_E="0.0" SE="0.23266374296463133" STUDY_ID="STD-Selkova-2005b" TOTAL_1="110" TOTAL_2="117" VAR="0.05413241729031203" WEIGHT="80.46285543624964"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-01-23 02:12:41 +1000" MODIFIED_BY="Robert T Mathie" NO="2">
<NAME>Treatment: Oscillococcinum versus placebo</NAME>
<DICH_OUTCOME CHI2="0.537701796031634" CI_END="2.7295736380016065" CI_START="1.2722758387819846" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8635371179039304" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.4360948151271857" LOG_CI_START="0.10458127976658085" LOG_EFFECT_SIZE="0.2703380474468833" METHOD="MH" MODIFIED="2013-01-23 02:12:41 +1000" MODIFIED_BY="Robert T Mathie" NO="1" NOTES="&lt;p&gt;Ferley: Data taken from Table 2: mean values at D2 (48 h; which corresponds with data extracted from Fig 2).&lt;/p&gt;&lt;p&gt;Papp: Data taken from Fig 2 (2 ev.).&lt;/p&gt;" NOTES_MODIFIED="2013-01-23 02:12:41 +1000" NOTES_MODIFIED_BY="Robert T Mathie" P_CHI2="0.46338682328521985" P_Q="1.0" P_Z="0.001390728748452962" Q="0.0" RANDOM="NO" SCALE="5.45" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="395" TOTAL_2="401" WEIGHT="100.0" Z="3.1965683456660225">
<NAME>Absence of symptoms at 48 hours - patient assessment</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.680854337794659" CI_START="1.0375177463461538" EFFECT_SIZE="1.667763157894737" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="24" LOG_CI_END="0.4282732175596903" LOG_CI_START="0.015995533889474233" LOG_EFFECT_SIZE="0.22213437572458225" MODIFIED="2012-03-27 20:24:46 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1613" O_E="0.0" SE="0.24217395219533278" STUDY_ID="STD-Ferley-1989" TOTAL_1="228" TOTAL_2="234" VAR="0.05864822312190733" WEIGHT="66.37554585152839"/>
<DICH_DATA CI_END="4.289691857810559" CI_START="1.180154698240698" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="12" LOG_CI_END="0.6324260965532748" LOG_CI_START="0.07193893966945022" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2012-03-27 20:24:55 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1614" O_E="0.0" SE="0.32923293040973095" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.10839432246617874" WEIGHT="33.62445414847162"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="68" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-07-28 03:00:22 +1000" MODIFIED_BY="Robert T Mathie" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.33" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="414" TOTAL_2="410" WEIGHT="0.0" Z="0.0">
<NAME>Absence of symptoms at 48 hours - patient assessment - by age</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.703031299635555" CI_START="0.5861147193038169" EFFECT_SIZE="1.2586844050258685" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.4318510746222569" LOG_CI_START="-0.2320173718923007" LOG_EFFECT_SIZE="0.09991685136497809" MODIFIED="2012-07-28 02:50:40 +1000" MODIFIED_BY="Robert T Mathie" ORDER="56" O_E="0.0" SE="0.3899596116844606" STUDY_ID="STD-Ferley-1989" TOTAL_1="123" TOTAL_2="131" VAR="0.1520684987450953" WEIGHT="0.0">
<FOOTNOTE>30+ yrs</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="7.226751957123034" CI_START="1.3155210668430295" EFFECT_SIZE="3.0833333333333335" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="6" LOG_CI_END="0.8589431487402263" LOG_CI_START="0.11909780729851414" LOG_EFFECT_SIZE="0.4890204780193702" MODIFIED="2012-07-28 02:50:26 +1000" MODIFIED_BY="Robert T Mathie" ORDER="55" O_E="0.0" SE="0.43458881585636655" STUDY_ID="STD-Ferley-1989" TOTAL_1="84" TOTAL_2="74" VAR="0.18886743886743887" WEIGHT="0.0">
<FOOTNOTE>12-29 yrs</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.4303772554324543" CI_START="1.1436289440402208" EFFECT_SIZE="1.9806763285024154" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="17" LOG_CI_END="0.5353418841661264" LOG_CI_START="0.05828513835950913" LOG_EFFECT_SIZE="0.29681351126281774" MODIFIED="2012-07-28 02:50:53 +1000" MODIFIED_BY="Robert T Mathie" ORDER="57" O_E="0.0" SE="0.28022549395578394" STUDY_ID="STD-Ferley-1989" TOTAL_1="207" TOTAL_2="205" VAR="0.07852632746276311" WEIGHT="0.0">
<FOOTNOTE>Totals</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="76" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-07-28 03:00:32 +1000" MODIFIED_BY="Robert T Mathie" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.87" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="448" TOTAL_2="466" WEIGHT="0.0" Z="0.0">
<NAME>Absence of symptoms at 48 hours - patient assessment - by severity of symptoms</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6064334549186494" CI_START="1.1949010589560265" EFFECT_SIZE="2.075892857142857" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" LOG_CI_END="0.5570779230980366" LOG_CI_START="0.07733194601354572" LOG_EFFECT_SIZE="0.31720493455579113" MODIFIED="2012-07-28 02:56:08 +1000" MODIFIED_BY="Robert T Mathie" ORDER="60" O_E="0.0" SE="0.28180516172031644" STUDY_ID="STD-Ferley-1989" TOTAL_1="126" TOTAL_2="135" VAR="0.07941414917221369" WEIGHT="0.0">
<FOOTNOTE>Mild to moderate</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.6535823776368974" CI_START="1.022181321637021" EFFECT_SIZE="1.6469494047619047" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="24" LOG_CI_END="0.42383257438402683" LOG_CI_START="0.009527940810093755" LOG_EFFECT_SIZE="0.21668025759706028" MODIFIED="2012-07-28 02:56:34 +1000" MODIFIED_BY="Robert T Mathie" ORDER="59" O_E="0.0" SE="0.24336459260234" STUDY_ID="STD-Ferley-1989" TOTAL_1="224" TOTAL_2="233" VAR="0.05922632493250292" WEIGHT="0.0">
<FOOTNOTE>Totals</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.319700009715043" CI_START="0.33005345380588713" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3654318243092715" LOG_CI_START="-0.4814157182646451" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2012-07-28 02:56:21 +1000" MODIFIED_BY="Robert T Mathie" ORDER="58" O_E="0.0" SE="0.4974424384708614" STUDY_ID="STD-Ferley-1989" TOTAL_1="98" TOTAL_2="98" VAR="0.2474489795918367" WEIGHT="0.0">
<FOOTNOTE>Severe</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2589094187944134" CI_START="0.9941976236941841" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.5130722894419908" LOG_CI_START="-0.0025272792353786275" LOG_EFFECT_SIZE="0.25527250510330607" METHOD="MH" MODIFIED="2012-07-19 02:29:16 +1000" MODIFIED_BY="Robert T Mathie" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.05228861557536932" Q="0.0" RANDOM="NO" SCALE="5.96" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="1.9407499410026454">
<NAME>Fitness for work at 2 days</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.2589094187944134" CI_START="0.9941976236941841" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" LOG_CI_END="0.5130722894419908" LOG_CI_START="-0.0025272792353786275" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2011-12-15 03:43:34 +1000" MODIFIED_BY="Robert T Mathie" ORDER="104" O_E="0.0" SE="0.3028657389001141" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.09172765579951207" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3006172524316089" CI_START="0.8291465954705315" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0384615384615385" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="78" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.114149510540827" LOG_CI_START="-0.08136867816448831" LOG_EFFECT_SIZE="0.016390416188169384" METHOD="MH" MODIFIED="2012-07-19 02:29:26 +1000" MODIFIED_BY="Robert T Mathie" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.7424504162398998" Q="0.0" RANDOM="NO" SCALE="6.16" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.00000000000001" Z="0.3286100964125896">
<NAME>Fitness for work at 4 days</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3006172524316089" CI_START="0.8291465954705316" EFFECT_SIZE="1.0384615384615385" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="78" LOG_CI_END="0.114149510540827" LOG_CI_START="-0.08136867816448826" LOG_EFFECT_SIZE="0.016390416188169384" MODIFIED="2011-12-15 03:51:31 +1000" MODIFIED_BY="Robert T Mathie" ORDER="105" O_E="0.0" SE="0.11484835187614527" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.01319014392866688" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.720018270256219" CI_END="1.6294882864799667" CI_START="1.0420732889984312" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3030910244785654" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="108" I2="41.86108268192773" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.21205124290156288" LOG_CI_START="0.01789826396188364" LOG_EFFECT_SIZE="0.11497475343172331" METHOD="MH" MODIFIED="2012-07-19 02:29:34 +1000" MODIFIED_BY="Robert T Mathie" NO="6" P_CHI2="0.18969079019403878" P_Q="1.0" P_Z="0.02026914665467827" Q="0.0" RANDOM="YES" SCALE="6.16" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.011431769975218562" TOTALS="YES" TOTAL_1="209" TOTAL_2="209" WEIGHT="100.0" Z="2.32132802791105">
<NAME>No chills at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.003746822437335" CI_START="1.122896353374188" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" LOG_CI_END="0.30184284665401634" LOG_CI_START="0.05033967145734618" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2011-12-15 03:57:54 +1000" MODIFIED_BY="Robert T Mathie" ORDER="107" O_E="0.0" SE="0.14773421007131973" STUDY_ID="STD-Casanova-1984" TOTAL_1="42" TOTAL_2="42" VAR="0.02182539682539683" WEIGHT="39.10912254947616"/>
<DICH_DATA CI_END="1.4472279183389838" CI_START="0.9792746133016104" EFFECT_SIZE="1.1904761904761905" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="84" LOG_CI_END="0.16053693186696932" LOG_CI_START="-0.009095503990732666" LOG_EFFECT_SIZE="0.07572071393811834" MODIFIED="2011-12-15 03:58:05 +1000" MODIFIED_BY="Robert T Mathie" ORDER="108" O_E="0.0" SE="0.09964293251691407" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.00992871400057029" WEIGHT="60.890877450523845"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.1213408724553965E-31" CI_END="2.91810209212838" CI_START="1.3390612986465653" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9767441860465118" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" I2="100.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.4651004819619534" LOG_CI_START="0.1268004583074592" LOG_EFFECT_SIZE="0.29595047013470627" METHOD="MH" MODIFIED="2012-07-19 02:29:43 +1000" MODIFIED_BY="Robert T Mathie" NO="7" P_CHI2="0.0" P_Q="1.0" P_Z="6.053231454483831E-4" Q="0.0" RANDOM="NO" SCALE="6.36" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="45" WEIGHT="100.0" Z="3.4292179847089144">
<NAME>No fever at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.918102092128379" CI_START="1.3390612986465653" EFFECT_SIZE="1.9767441860465116" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" LOG_CI_END="0.46510048196195325" LOG_CI_START="0.1268004583074592" LOG_EFFECT_SIZE="0.2959504701347062" MODIFIED="2011-12-15 04:01:26 +1000" MODIFIED_BY="Robert T Mathie" ORDER="109" O_E="0.0" SE="0.19871910850677474" STUDY_ID="STD-Casanova-1984" TOTAL_1="43" TOTAL_2="45" VAR="0.039489284085727314" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.7002645757575756" CI_START="0.6583716994765267" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.43140631903386073" LOG_CI_START="-0.1815288458172609" LOG_EFFECT_SIZE="0.12493873660829993" METHOD="MH" MODIFIED="2012-07-19 02:29:52 +1000" MODIFIED_BY="Robert T Mathie" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.4242756129157822" Q="0.0" RANDOM="NO" SCALE="6.36" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="24" WEIGHT="100.0" Z="0.7990255350602463">
<NAME>No rhinitis at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.7002645757575756" CI_START="0.6583716994765267" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.43140631903386073" LOG_CI_START="-0.1815288458172609" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2011-12-15 04:04:41 +1000" MODIFIED_BY="Robert T Mathie" ORDER="110" O_E="0.0" SE="0.3600411499115478" STUDY_ID="STD-Casanova-1984" TOTAL_1="27" TOTAL_2="24" VAR="0.12962962962962962" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5853901562250963" CI_START="1.1602239419916835" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7319444444444445" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.41252609091540104" LOG_CI_START="0.06454182317914733" LOG_EFFECT_SIZE="0.23853395704727418" METHOD="MH" MODIFIED="2012-07-19 02:30:00 +1000" MODIFIED_BY="Robert T Mathie" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.007209558666375365" Q="0.0" RANDOM="NO" SCALE="6.16" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="43" WEIGHT="100.0" Z="2.6870063290149986">
<NAME>No general aches at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5853901562250963" CI_START="1.1602239419916835" EFFECT_SIZE="1.7319444444444445" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="18" LOG_CI_END="0.41252609091540104" LOG_CI_START="0.06454182317914733" LOG_EFFECT_SIZE="0.23853395704727418" MODIFIED="2011-12-15 04:12:44 +1000" MODIFIED_BY="Robert T Mathie" ORDER="111" O_E="0.0" SE="0.2044076814181816" STUDY_ID="STD-Casanova-1984" TOTAL_1="40" TOTAL_2="43" VAR="0.04178250022275683" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6327987613922068" CI_START="0.881921296150533" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.21293266226121482" LOG_CI_START="-0.05457017016596517" LOG_EFFECT_SIZE="0.07918124604762482" METHOD="MH" MODIFIED="2012-07-19 02:30:07 +1000" MODIFIED_BY="Robert T Mathie" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.24592481095234897" Q="0.0" RANDOM="NO" SCALE="2.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="1.1603046524495841">
<NAME>No headache at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6327987613922068" CI_START="0.881921296150533" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="50" LOG_CI_END="0.21293266226121482" LOG_CI_START="-0.05457017016596517" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2010-12-22 02:02:17 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1632" O_E="0.0" SE="0.15713248792810178" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.024690618762475053" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.609148286228686" CI_START="1.0002122724714135" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2686567164179106" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.20659606704712163" LOG_CI_START="9.217897981102685E-5" LOG_EFFECT_SIZE="0.10334412301346634" METHOD="MH" MODIFIED="2012-07-19 02:30:14 +1000" MODIFIED_BY="Robert T Mathie" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.04979581919540855" Q="0.0" RANDOM="NO" SCALE="2.1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="1.961713757701733">
<NAME>No backache at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.609148286228686" CI_START="1.0002122724714135" EFFECT_SIZE="1.2686567164179106" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="67" LOG_CI_END="0.20659606704712163" LOG_CI_START="9.217897981102685E-5" LOG_EFFECT_SIZE="0.10334412301346634" MODIFIED="2010-12-22 02:03:48 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1633" O_E="0.0" SE="0.12130140606147022" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.014714031112489685" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5769611076352148" CI_START="1.0232253361988193" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2702702702702702" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="74" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="0.19782098251869384" LOG_CI_START="0.009971285218750976" LOG_EFFECT_SIZE="0.10389613386872243" METHOD="MH" MODIFIED="2012-07-19 02:30:22 +1000" MODIFIED_BY="Robert T Mathie" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.03015576343182335" Q="0.0" RANDOM="NO" SCALE="2.11" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="2.168038420530476">
<NAME>No spinal pain at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5769611076352148" CI_START="1.0232253361988193" EFFECT_SIZE="1.2702702702702702" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="74" LOG_CI_END="0.19782098251869384" LOG_CI_START="0.009971285218750976" LOG_EFFECT_SIZE="0.10389613386872243" MODIFIED="2010-12-22 02:06:13 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1634" O_E="0.0" SE="0.11034384206498488" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.012175763481662326" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.969281324105165" CI_START="1.0963900121405474" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.469387755102041" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="0.29430776224232086" LOG_CI_START="0.03996507056318878" LOG_EFFECT_SIZE="0.1671364164027548" METHOD="MH" MODIFIED="2012-07-19 02:30:29 +1000" MODIFIED_BY="Robert T Mathie" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.009997799503831879" Q="0.0" RANDOM="NO" SCALE="2.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="2.5759054014239324">
<NAME>No muscle pain at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.969281324105165" CI_START="1.0963900121405474" EFFECT_SIZE="1.469387755102041" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="49" LOG_CI_END="0.29430776224232086" LOG_CI_START="0.03996507056318878" LOG_EFFECT_SIZE="0.1671364164027548" MODIFIED="2010-12-22 02:08:05 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1635" O_E="0.0" SE="0.1494021561089511" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.0223210042500034" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8021146730111253" CI_START="1.0876111433713962" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="60" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.2557824227537066" LOG_CI_START="0.03647364860276938" LOG_EFFECT_SIZE="0.146128035678238" METHOD="MH" MODIFIED="2012-07-19 02:30:36 +1000" MODIFIED_BY="Robert T Mathie" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.009004204390300363" Q="0.0" RANDOM="NO" SCALE="2.15" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="2.6118944686072116">
<NAME>No articular pain at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8021146730111253" CI_START="1.0876111433713964" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="60" LOG_CI_END="0.2557824227537066" LOG_CI_START="0.036473648602769464" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2010-12-22 02:11:41 +1000" MODIFIED_BY="Robert T Mathie" ORDER="61" O_E="0.0" SE="0.1288230595322008" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.016595380667236953" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.8406599203589056" CI_START="0.7344841732490136" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.4534192437362835" LOG_CI_START="-0.13401755800125975" LOG_EFFECT_SIZE="0.15970084286751188" METHOD="MH" MODIFIED="2012-09-08 01:36:13 +1000" MODIFIED_BY="Robert T Mathie" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.2865713013728667" Q="0.0" RANDOM="NO" SCALE="6.11" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="1.0656734457057742">
<NAME>No night cough at 48 hours</NAME>
<GROUP_LABEL_1>Favours placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8406599203589056" CI_START="0.7344841732490136" EFFECT_SIZE="1.4444444444444444" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.4534192437362835" LOG_CI_START="-0.13401755800125975" LOG_EFFECT_SIZE="0.15970084286751188" MODIFIED="2010-12-22 02:12:23 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1636" O_E="0.0" SE="0.34506328519969887" STUDY_ID="STD-Casanova-1984" TOTAL_1="29" TOTAL_2="29" VAR="0.11906867079280871" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3132386165493113" CI_START="1.2019886998621243" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9956140350877194" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.520252714517306" LOG_CI_START="0.07990038479601132" LOG_EFFECT_SIZE="0.30007654965665864" METHOD="MH" MODIFIED="2012-07-19 02:30:53 +1000" MODIFIED_BY="Robert T Mathie" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.007557583497495484" Q="0.0" RANDOM="NO" SCALE="5.92" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="35" WEIGHT="100.0" Z="2.6712211574051983">
<NAME>No day cough at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3132386165493113" CI_START="1.2019886998621243" EFFECT_SIZE="1.9956140350877194" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="12" LOG_CI_END="0.520252714517306" LOG_CI_START="0.07990038479601132" LOG_EFFECT_SIZE="0.30007654965665864" MODIFIED="2010-12-22 02:12:53 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1637" O_E="0.0" SE="0.25866513825747567" STUDY_ID="STD-Casanova-1984" TOTAL_1="38" TOTAL_2="35" VAR="0.06690765374975902" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.32528081741897186" CI_START="-0.6747191825810281" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.17" MODIFIED="2012-07-19 02:31:00 +1000" MODIFIED_BY="Robert T Mathie" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="2.036195281698879E-8" Q="0.0" RANDOM="NO" SCALE="1.11" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="150" TOTAL_2="150" UNITS="" WEIGHT="100.0" Z="5.608897533706972">
<NAME>Temperature at 48 hours</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oscillococcinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.32528081741897186" CI_START="-0.6747191825810281" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="38.7" MEAN_2="39.2" MODIFIED="2011-12-15 04:18:17 +1000" MODIFIED_BY="Robert T Mathie" ORDER="112" SD_1="0.52" SD_2="0.96" SE="0.08914407813571616" STUDY_ID="STD-Casanova-1988" TOTAL_1="150" TOTAL_2="150" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1775407491300958" CI_START="0.9787053218967201" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0735294117647058" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="136" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="0.07097594494414607" LOG_CI_START="-0.009348050115706944" LOG_EFFECT_SIZE="0.030813947414219566" METHOD="MH" MODIFIED="2012-07-19 02:31:07 +1000" MODIFIED_BY="Robert T Mathie" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.13264175178530507" Q="0.0" RANDOM="NO" SCALE="2.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="1.5037655213334213">
<NAME>Improvement in symptoms at 48 hours - physician assessment</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1775407491300958" CI_START="0.9787053218967202" EFFECT_SIZE="1.0735294117647058" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="136" LOG_CI_END="0.07097594494414607" LOG_CI_START="-0.009348050115706896" LOG_EFFECT_SIZE="0.030813947414219566" MODIFIED="2011-09-23 01:24:05 +1000" MODIFIED_BY="Robert T Mathie" ORDER="52" O_E="0.0" SE="0.047182712308345746" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.002226208340772121" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.062745085187088" CI_START="0.7942813737701377" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.3144455610138712" LOG_CI_START="-0.10002562171813445" LOG_EFFECT_SIZE="0.10720996964786837" METHOD="MH" MODIFIED="2012-07-23 14:56:08 +1000" MODIFIED_BY="Robert T Mathie" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.3106039738196472" Q="0.0" RANDOM="NO" SCALE="5.81" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="1.013955556130046">
<NAME>Absence of symptoms at 48 hours - physician assessment</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.062745085187088" CI_START="0.7942813737701377" EFFECT_SIZE="1.28" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="25" LOG_CI_END="0.3144455610138712" LOG_CI_START="-0.10002562171813445" LOG_EFFECT_SIZE="0.10720996964786837" MODIFIED="2011-09-22 22:22:16 +1000" MODIFIED_BY="Robert T Mathie" ORDER="54" O_E="0.0" SE="0.2434624244022235" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.05927395209580839" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.005447616074624822" CI_END="1.5643358752060967" CI_START="1.0286639519851688" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2685329808963113" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="109" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.19433000517390064" LOG_CI_START="0.01227352089008175" LOG_EFFECT_SIZE="0.10330176303199118" METHOD="MH" MODIFIED="2012-07-23 14:56:18 +1000" MODIFIED_BY="Robert T Mathie" NO="20" NOTES="&lt;p&gt;Ferley: Data taken from Table 2: mean values at D3.&lt;/p&gt;&lt;p&gt;Papp: Data taken from Fig 2 (3 ev.).&lt;/p&gt;" NOTES_MODIFIED="2012-07-23 14:56:18 +1000" NOTES_MODIFIED_BY="Robert T Mathie" P_CHI2="0.9411631872185163" P_Q="1.0" P_Z="0.026132982419598636" Q="0.0" RANDOM="NO" SCALE="5.55" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="395" TOTAL_2="401" WEIGHT="100.0" Z="2.2242298688637168">
<NAME>Absence of symptoms at 3 days - patient assessment</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6311393029914496" CI_START="0.9747018512520623" EFFECT_SIZE="1.2609022556390976" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="70" LOG_CI_END="0.21249105235668922" LOG_CI_START="-0.01112820907868936" LOG_EFFECT_SIZE="0.1006814216389999" MODIFIED="2010-12-21 03:44:03 +1000" MODIFIED_BY="Robert T Mathie" ORDER="50" O_E="0.0" SE="0.13135506110033787" STUDY_ID="STD-Ferley-1989" TOTAL_1="228" TOTAL_2="234" VAR="0.017254152076673496" WEIGHT="63.919259882253996"/>
<DICH_DATA CI_END="1.8368936492295571" CI_START="0.8948016617612727" EFFECT_SIZE="1.2820512820512822" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="39" LOG_CI_END="0.2640840126532303" LOG_CI_START="-0.04827321803419106" LOG_EFFECT_SIZE="0.10790539730951963" MODIFIED="2010-12-21 03:49:28 +1000" MODIFIED_BY="Robert T Mathie" ORDER="51" O_E="0.0" SE="0.18348018349901993" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.03366497773683402" WEIGHT="36.080740117746004"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.02313582302548909" CI_END="1.2694233000032797" CI_START="0.9792363606795564" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.114928451721026" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="203" I2="0.0" I2_Q="100.0" ID="CMP-002.21" LOG_CI_END="0.10360646543688322" LOG_CI_START="-0.009112468820543848" LOG_EFFECT_SIZE="0.047246998308169676" METHOD="MH" MODIFIED="2012-07-23 14:56:29 +1000" MODIFIED_BY="Robert T Mathie" NO="21" NOTES="&lt;p&gt;Ferley: Data taken from Table 2: mean values at D4.&lt;/p&gt;&lt;p&gt;Papp: Data taken from Fig 2 (4 ev.).&lt;/p&gt;" NOTES_MODIFIED="2012-07-23 14:56:29 +1000" NOTES_MODIFIED_BY="Robert T Mathie" P_CHI2="0.8791044148570295" P_Q="0.0" P_Z="0.10036894508434813" Q="4.393104496798211E-32" RANDOM="NO" SCALE="5.55" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="395" TOTAL_2="401" WEIGHT="100.0" Z="1.6430676118734833">
<NAME>Absence of symptoms at 4 days - patient assessment</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3144908664816626" CI_START="0.9293382550988519" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="117" LOG_CI_END="0.11875757283082199" LOG_CI_START="-0.031826185268641276" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2010-12-21 03:58:10 +1000" MODIFIED_BY="Robert T Mathie" ORDER="52" O_E="0.0" SE="0.08845364490924898" STUDY_ID="STD-Ferley-1989" TOTAL_1="228" TOTAL_2="234" VAR="0.007824047297731508" WEIGHT="57.31597266984659"/>
<DICH_DATA CI_END="1.3716012647586668" CI_START="0.9275101889119713" EFFECT_SIZE="1.127906976744186" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="86" LOG_CI_END="0.13722787690766064" LOG_CI_START="-0.03268131086230637" LOG_EFFECT_SIZE="0.052273283022677135" MODIFIED="2010-12-21 03:54:19 +1000" MODIFIED_BY="Robert T Mathie" ORDER="53" O_E="0.0" SE="0.09980549796012257" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.009961137423068032" WEIGHT="42.684027330153405"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.006238081120035294" CI_END="1.1619333678644" CI_START="0.9612021532223515" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.056812592228234" ESTIMABLE="YES" EVENTS_1="277" EVENTS_2="266" I2="0.0" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.06518122375265112" LOG_CI_START="-0.017185264988884348" LOG_EFFECT_SIZE="0.023997979381883375" METHOD="MH" MODIFIED="2012-07-23 14:56:43 +1000" MODIFIED_BY="Robert T Mathie" NO="22" NOTES="&lt;p&gt;Ferley: Data taken from Table 2: mean values at D5.&lt;/p&gt;&lt;p&gt;Papp: Data taken from Fig 2 (5 ev.).&lt;/p&gt;" NOTES_MODIFIED="2012-07-23 14:56:43 +1000" NOTES_MODIFIED_BY="Robert T Mathie" P_CHI2="0.9370473190732407" P_Q="1.0" P_Z="0.25341457481217966" Q="0.0" RANDOM="NO" SCALE="5.73" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="395" TOTAL_2="401" WEIGHT="99.99999999999999" Z="1.1420949468374628">
<NAME>Absence of symptoms at 5 days - patient assessment</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oscillococcinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1983169274008085" CI_START="0.9258749782194744" EFFECT_SIZE="1.0533240997229918" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="152" LOG_CI_END="0.0785716941955622" LOG_CI_START="-0.03344765255680594" LOG_EFFECT_SIZE="0.02256202081937814" MODIFIED="2010-12-18 04:22:42 +1000" MODIFIED_BY="Robert T Mathie" ORDER="53" O_E="0.0" SE="0.06580071878705039" STUDY_ID="STD-Ferley-1989" TOTAL_1="228" TOTAL_2="234" VAR="0.004329734592892487" WEIGHT="56.82242990654205"/>
<DICH_DATA CI_END="1.2202018444127216" CI_START="0.9232713534993724" EFFECT_SIZE="1.0614035087719298" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="114" LOG_CI_END="0.08643167712060568" LOG_CI_START="-0.03467063916065071" LOG_EFFECT_SIZE="0.025880518979977476" MODIFIED="2010-12-18 04:28:43 +1000" MODIFIED_BY="Robert T Mathie" ORDER="54" O_E="0.0" SE="0.07113610004974368" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.005060344730287141" WEIGHT="43.17757009345794"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9245332453324937" CI_START="0.4007540008387446" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="46" I2="0.0" I2_Q="99.99999999999999" ID="CMP-002.23" LOG_CI_END="-0.034077467409237734" LOG_CI_START="-0.3971221332694719" LOG_EFFECT_SIZE="-0.21559980033935483" METHOD="MH" MODIFIED="2012-07-30 22:27:01 +1000" MODIFIED_BY="Robert T Mathie" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.019916827643993947" Q="6.775871229898458E-32" RANDOM="NO" SCALE="6.16" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="167" TOTAL_2="167" WEIGHT="100.0" Z="2.327911044983337">
<NAME>Increased use of concomitant medication during trial</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oscillococcinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9245332453324937" CI_START="0.4007540008387446" EFFECT_SIZE="0.6086956521739131" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="46" LOG_CI_END="-0.034077467409237734" LOG_CI_START="-0.3971221332694719" LOG_EFFECT_SIZE="-0.21559980033935483" MODIFIED="2011-10-26 23:46:03 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1644" O_E="0.0" SE="0.2132542338263808" STUDY_ID="STD-Papp-1998" TOTAL_1="167" TOTAL_2="167" VAR="0.045477368244876706" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8100458269015693E-30" CI_END="0.998575243658266" CI_START="0.6664620113511583" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8157894736842104" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="117" I2="100.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="-6.192050302385308E-4" LOG_CI_START="-0.17622460053483657" LOG_EFFECT_SIZE="-0.08842190278253755" METHOD="MH" MODIFIED="2012-07-30 22:27:08 +1000" MODIFIED_BY="Robert T Mathie" NO="24" P_CHI2="0.0" P_Q="1.0" P_Z="0.04840606934309498" Q="0.0" RANDOM="NO" SCALE="2.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="228" TOTAL_2="234" WEIGHT="100.0" Z="1.9737861060623032">
<NAME>Medication used for pain or fever</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oscillococcinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9985752436582661" CI_START="0.6664620113511585" EFFECT_SIZE="0.8157894736842105" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="117" LOG_CI_END="-6.192050302384825E-4" LOG_CI_START="-0.17622460053483652" LOG_EFFECT_SIZE="-0.08842190278253749" MODIFIED="2011-10-26 23:25:54 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1641" O_E="0.0" SE="0.1031514785801279" STUDY_ID="STD-Ferley-1989" TOTAL_1="228" TOTAL_2="234" VAR="0.010640227533266584" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2081552994914326" CI_START="0.7618342708937427" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9593821510297483" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="92" I2="0.0" I2_Q="0.0" ID="CMP-002.25" LOG_CI_END="0.08212276323971594" LOG_CI_START="-0.11813949462431286" LOG_EFFECT_SIZE="-0.018008365692298477" METHOD="MH" MODIFIED="2012-07-30 22:27:19 +1000" MODIFIED_BY="Robert T Mathie" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.7244668744138394" Q="0.0" RANDOM="NO" SCALE="2.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="228" TOTAL_2="234" WEIGHT="100.00000000000001" Z="0.3524952585054378">
<NAME>Medication used for cough or coryza</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oscillococcinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2081552994914326" CI_START="0.7618342708937427" EFFECT_SIZE="0.9593821510297483" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="92" LOG_CI_END="0.08212276323971594" LOG_CI_START="-0.11813949462431286" LOG_EFFECT_SIZE="-0.018008365692298477" MODIFIED="2011-10-26 23:30:50 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1642" O_E="0.0" SE="0.11763504158349465" STUDY_ID="STD-Ferley-1989" TOTAL_1="228" TOTAL_2="234" VAR="0.013838003008350514" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6221619546066481" CI_START="0.4691434538263474" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8723684210526316" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-002.26" LOG_CI_END="0.21009421145389234" LOG_CI_START="-0.3286943392059288" LOG_EFFECT_SIZE="-0.05930006387601822" METHOD="MH" MODIFIED="2012-07-30 22:27:25 +1000" MODIFIED_BY="Robert T Mathie" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.6661524567196664" Q="0.0" RANDOM="NO" SCALE="5.96" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="228" TOTAL_2="234" WEIGHT="100.00000000000001" Z="0.43143451855309706">
<NAME>Antibiotics used</NAME>
<GROUP_LABEL_1>Oscillococcinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Oscillococcinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6221619546066481" CI_START="0.4691434538263474" EFFECT_SIZE="0.8723684210526316" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.21009421145389234" LOG_CI_START="-0.3286943392059288" LOG_EFFECT_SIZE="-0.05930006387601822" MODIFIED="2011-10-26 23:35:39 +1000" MODIFIED_BY="Robert T Mathie" ORDER="1643" O_E="0.0" SE="0.3164870617039182" STUDY_ID="STD-Ferley-1989" TOTAL_1="228" TOTAL_2="234" VAR="0.10016406022597973" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-01-31 20:16:58 +1000" MODIFIED_BY="Robert T Mathie">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-11-14 21:12:00 +1000" MODIFIED_BY="Robert T Mathie" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUIAAAIJCAIAAABfuKP5AAAWE0lEQVR42u3dv45kRxXH8ZGQEMEG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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-01-31 20:16:58 +1000" MODIFIED_BY="Robert T Mathie" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Prevention: Oscillococcinum versus placebo. Outcome 1: Occurrence of influenza-like illness.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0cAAACgCAMAAADwzecWAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-01-30 22:33:33 +1000" MODIFIED_BY="Robert T Mathie" NO="3" REF_ID="CMP-002.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Treatment: Oscillococcinum versus placebo. Outcome 1: Absence of symptoms at 48 hours - patient assessment.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzYAAACgCAMAAADpRgmwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-01-30 22:34:45 +1000" MODIFIED_BY="Robert T Mathie" NO="4" REF_ID="CMP-002.20" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Treatment: Oscillococcinum versus placebo. Outcome 20: Absence of symptoms at 3 days - patient assessment.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzYAAACgCAMAAADpRgmwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-01-30 22:35:13 +1000" MODIFIED_BY="Robert T Mathie" NO="5" REF_ID="CMP-002.21" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Treatment: Oscillococcinum versus placebo. Outcome 21: Absence of symptoms at 4 days - patient assessment.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzYAAACgCAMAAADpRgmwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2013-01-30 22:35:54 +1000" MODIFIED_BY="Robert T Mathie" NO="6" REF_ID="CMP-002.22" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Treatment: Oscillococcinum versus placebo. Outcome 22: Absence of symptoms at 5 days - patient assessment.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAzYAAACgCAMAAADpRgmwAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-01-14 22:04:17 +1000" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2013-04-16 08:24:33 +1000" MODIFIED_BY="Robert T Mathie" NO="1">
<TITLE>Reported side effects</TITLE>
<DATE_SUBMITTED>
<DATE DAY="4" MONTH="3" YEAR="2003"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-04-16 08:24:25 +1000" MODIFIED_BY="Robert T Mathie">
<P>Were there any side effects reported, relating to this study (or any known side effects related to this product)?</P>
<P>Cindy Haberfield</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-04-16 08:24:30 +1000" MODIFIED_BY="Robert T Mathie">
<P>Adverse events are discussed in the review.<BR/>A review on the safety of homeopathy is available at: http://climed.epm.br/homeopatia/SafetyHomeopathyReview2000.pdf</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-04-16 08:24:33 +1000" MODIFIED_BY="Robert T Mathie">
<P>Andrew Vickers</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2015-01-14 22:04:17 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-04-16 08:25:30 +1000" MODIFIED_BY="[Empty name]">Homeopathic Oscillococcinum® for preventing and treating influenza and influenza&#8208;like illness</TITLE>
<DATE_SUBMITTED>
<DATE DAY="8" MONTH="1" YEAR="2013"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2015-01-14 21:14:47 +1000" MODIFIED_BY="[Empty name]">
<P>Comment: I do not believe that this is an appropriate subject for the Cochrane library, or that the reviewers are appropriate, or that the conclusion is appropriate. </P>
<P>Oscillococcinum was invented between 1917 and around 1925 by one Joseph Roy (1891-1978), a French physician on military duty during the Spanish flue epidemic of 1917 onwards. It is based on his purported discovery using (optical) microscopy of a bacterium in the blood of flu victims, which he named oscillococcus due to its motion. He later identified this bacterium in patients with many other disorders, and posted it as a causative agent in herpes, chicken pox, shingles, eczema, rheumatism, tuberculosis, measles, and cancer. He then searched for the bacterium in animals, finding it eventually in the liver of a Long Island duckling. The remedy Oscillococcinum(R) is prepared from the heart and liver of a Muscovy duck, and the label states: "Active ingredient: Anas Barbariae Hepatis et Cordis Extractum (extract of Muscovy Duck liver and heart) 200CK HPUS 1×10^&#8722;400 g; Inactive ingredient: 0.85 g sucrose, 0.15 g lactose.[1] </P>
<P>There are a number of fundamental issues to be addressed before one even considers evaluating this commercial and trademarked product: </P>
<P>1. The oscillococcus bacterium does not exist. Whatever Roy saw, it was not an oscillococcus bacterium.</P>
<P>2. Influenza is not caused by a bacterium. The virus that causes flu is not visible in an optical microscope.</P>
<P>3. The large list of other proposed conditions, which are now known to have entirely different causes, indicates systemic false attribution.</P>
<P>4. The idea of a preparation from a source believed to contain the actual pathogen, albeit incorrectly identified, is not consistent with the (unproven) homeopathic principle of similia similibus curentur; this particular version of the archaic principle of sympathetic magic is based on *like* not *same* curing same. There is no inferential link, even according to the odd doctrines of homeopathy, linking duck liver and influenza. There is no record of consumption of duck liver, a common foodstuff, causing flu-like symptoms in healthy individuals.</P>
<P>5. The ingredients listed are preposterous. There is no instrument known to science that is capable of measuring dilutions of one part in ten to the minus four hundredth power, this is billions of orders of magnitude greater than the number of atoms in the known universe. No objective test is identified (or indeed plausible) that shows Oscillococcinum tablets to be anything other than 100.0% sugar. </P>
<P>The authors, who have an ideological disposition towards homeopathy, have in effect taken a number of weak observational studies of a substance that is objectively indistinguishable from a sugar pill, for which there is no credible reason to believe any relevant effect should arise, even according to the principles of homeopathy, and concluded from these that their findings "do not rule out the possibility that Oscillococcinum® could have a clinically useful treatment effect". </P>
<P>Observational studies are, by their very nature, not capable of refuting the null hypothesis. The typical test of significance, P=0.05, explicitly allows for the fact that a false result is not only possible but expected. No such study can rule out a  possibility of clinical effect. </P>
<P>The consensus from systematic reviews is that the effects of homeopathic remedies are placebo effects.[2] </P>
<P>This review could therefore be summarised thus: </P>
<P>Three authors with a known predisposition towards homeopathy[3], reviewed the literature supporting a commercial product whose manufacturers have recently settled class actions accepting that their claims cannot be substantiated as made[4]. The evidence was found to be weak, consistent with the documented correlation between study quality and negative results for homeopathy[5]. Reviewing a number of studies which are not capable, by design, of ruling out clinical effect, the authors conclude that these poor quality studies do not rule out clinical effect. </P>
<P>The value of this negative finding, spun by the authors as cautiously positive, would appear to be negligible compared with the vastly more robust finding, based n a much broader evidence base, that the effects of homeopathy are placebo effects [6]. This study is already being presented by homeopaths as cautiously supportive, and as an indication of the need for "more research" [7]. </P>
<P>Can we really not just have a moratorium on tooth fairy science [8] in the Cochrane library? </P>
<P>1. The True Story of Oscillococcinum, Jan Willem Nienhuys, Homeopwatch, August 2003 <A HREF="http://www.homeowatch.org/history/oscillo.html">http://www.homeowatch.org/history/oscillo.html</A>
</P>
<P>2. A systematic review of systematic reviews of homeopathy, Ernst E, Br J Clin Pharmacol. 2002 Dec;54(6):577-82.</P>
<P>3. See author affiliations</P>
<P>4. Class action settlement agreement: Galluci and others v. Boiron Inc and Boiron USA Inc., US District Court, Southern District of California case 3:11-cv-02039-JAH-NLS <A HREF="http://www.gilardi.com/boironsettlement/pdf/BRGL_SettlementAgreement.pdf">http://www.gilardi.com/boironsettlement/pdf/BRGL_SettlementAgreement.pdf</A>
</P>
<P>5. Impact of study quality on outcome in placebo-controlled trials of homeopathy. Linde K, Scholz M, Ramirez G, Clausius N, Melchart D, Jonas WB. J Clin Epidemiol. 1999 Jul;52(7):631-6.</P>
<P>6. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Shang A, Huwiler-Müntener K, Nartey L, Jüni P, Dörig S, Sterne JA, Pewsner D, Egger M. Lancet. 2005 Aug 27-Sep 2;366(9487):726-32.</P>
<P>7. e.g. Homoeopathic Oscillococcinum for preventing and treating influenza and influenza-like syndromes, Vickers A, Smith C, The Homeopathic College <A HREF="http://www.thehomeopathiccollege.org/portfolio-view/homoeopathic-oscillococcinum-for-preventing-and-treating-influenza-and-influenza-like-syndromes/">http://www.thehomeopathiccollege.org/portfolio-view/homoeopathic-oscillococcinum-for-preventing-and-treating-influenza-and-influenza-like-syndromes/</A>
</P>
<P>8. Evidence-Based Medicine, Tooth Fairy Science, and Cinderella Medicine, Hall, H, Skeptic Vol 17, No. 1, p. 4-5. </P>
<P>I agree with the conflict of interest statement below:<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
<P>Guy Chapman<BR/>Role: Skeptical activist<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2015-01-14 22:04:17 +1000" MODIFIED_BY="[Empty name]">
<P>We appreciate Mr Chapman's description of the interesting history of the 1917 observation that led to the development of Oscillococcinum<SUP>®</SUP>. Dr Roy's mischaracterisation of his observations might perhaps be forgiven, given that viruses were only first visualised after the development of the transmission electron microscope in 1932.[i] Prior to that time, experimental transmission of influenza symptoms from infected to uninfected animals was attributed to an 'ultrafiltered material'.[ii] The annals of medicine are replete with medicines that changed direction during their development: e.g. sildenafil citrate (Viagra), which failed in its trials as an anti-hypertensive, but found new life in one of its 'adverse effects'. </P>
<P>Our review makes the following points about Oscillococcinum<SUP>®</SUP>: "The rationale for its use in influenza is not the standard homeopathic principle of 'let like be cured by like', but the related principle of 'isopathy': that a medicine derived from the causative agent of the disease, or from a product of the disease process, is used to treat the condition". And the assertion that there is 'no inferential link [between] duck liver and influenza' is simply false: it is 'hypothesised that wild aquatic birds are the primordial reservoir of all influenza A viruses'.[iii] However, water fowl do not generally become ill with the virus they harbour. </P>
<P>In our review, we directly address the subject of high dilution (<I>How the intervention might work</I>). Studies in recent decades with a variety of instruments have demonstrated the ability to distinguish various homeopathic medicines as well as different potencies of the same medicines. Recent studies reveal that homeopathic remedies contain nanoparticles of source materials formed by mechanical grinding in lactose and/or succussion (forceful agitation) in ethanolic solutions combined with silica nanostructures formed during succussions in glass.[iv] Other studies using various physical and physico-chemical methods have demonstrated persistent structural modifications as a result of homeopathic preparation methods.<SUP>e.g. [v], [vi],</SUP> [vii] These technologies have not yet been applied to Oscillococcinum<SUP>®</SUP>, but the assertion that no such instrument exists is incorrect. </P>
<P>Similarly, it is unclear why Mr Chapman characterises randomised controlled trials as 'observational studies'. Consistent with standard Cochrane methods, our conclusions were based on experimental research: i.e. randomised controlled trials, not observational studies. We refer him to further information on the subject of clinical study design.[viii] Given his expressed concerns about conflict of interest, it is interesting that he nevertheless accepts the evidence from an article published in 2002 by a 'trained homeopath' (see <I>Conflict of interest</I> in his reference no. 2). Even in 2002, when that article was published, there was no 'consensus' of evidence from systematic reviews of homeopathy. More recently, systematic reviews have reported positive conclusions about homeopathy in several medical conditions.<SUP>e.g. [ix], [x]</SUP>
</P>
<P>We are open-minded scientists who strive to know the facts about homeopathy and, most importantly, its potential contribution to the welfare of patients. Our review was conducted to rigorous standards of objectivity, as required by the Cochrane Collaboration. The conclusions are supported by correct interpretation of the statistical facts, and recognising the limitations of the original clinical trials. Mr Chapman's reference to the previous version (and authorship) of our review is bizarre, especially since the conclusions of our updated version are considerably more cautious than those of its predecessor. And, as we state in the section <I>Agreements and disagreements with other studies</I>, our conclusions are also less positively positioned than those of other previous reviews of Oscillococcinum. We stand by our</P>
<P>statement (<I>Implications for research</I>): "The two treatment trials (Ferley 1989, Papp 1998) yielded combined data that showed an absolute risk reduction of 7.7%; the total sample size of 796 participants provided sufficient statistical power to detect that substantial treatment effect. However, the quality of the evidence from these treatment trials is considerably less than robust, and further research is indicated." As scientists, we want to see much more robust evidence before making any definitive pronouncement about the efficacy or otherwise of Oscillococcinum<SUP>®</SUP>. </P>
<P>Boiron's expedient settlement of a harassing suit does not confirm that 'their claims cannot be substantiated as made'. Indeed, careful reading of the settlement of <I>Gallucci v. Boiron Inc. et al</I>. (the California class action suit that refers), reveals in Terms and Conditions of Settlement 2.1: 'Defendants deny the material factual allegations and legal claims asserted by the Representative Plaintiffs in the Litigation, including any and all charges of wrongdoing or liability arising out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Litigation'.[1] </P>
<P>Mr Chapman challenges the Cochrane Collaboration's criteria for subject selection, the reviewers' credentials and the statistical conclusions from factual data. These are serious allegations. Does he therefore: advocate arbitrary removal of other subject areas from Cochrane's formal review process (e.g. acupuncture, cognitive behaviour therapy, physiotherapy); dispute that an expert in a particular branch of medicine or science is appropriate to review research in that specialist field; dismiss the robust statistical methods that are accepted by the entire scientific community? </P>
<P>The respondent is well-known for his anti-homeopathy views,[2] and has posted identical allegations as above on his personal website.[3] Unfortunately he appears to be unaware of the difference between experimental and observational studies or of physical research on high dilutions. He substitutes these gaps in his knowledge with rhetoric about 'tooth-fairy science'. </P>
<P>Mr Chapman's submitted comments could be summarised thus: </P>
<P>A respondent with a known predisposition to condemn homeopathy finds that the Cochrane Collaboration must adopt a prejudiced approach to subject selection, and ensure that reviewers take a close-minded attitude to the available evidence by ignoring factual evidence provided by standard statistical methods and risk-of-bias assessments. Furthermore, he advises reviewers to ignore modern interpretations of drug discovery and to disregard the difference between experiment and observation. He advocates selective reading and referencing from the wider research literature, where conclusions against homeopathy must always prevail in the face of any evidence to the contrary that may emerge.  </P>
<P>
<B>References</B>
</P>
<P>1. Roingeard P. Viral detection by electron microscopy: past, present and future. <I>Biol Cell</I> 2008; <B>100</B>: 491&#8211;501. (doi:10.1042/BC20070173)</P>
<P>2. Shope RE. Swine influenza. III. Filtration experiments and aetiology. <I>J Exp Med</I> 1931; <B>54</B>: 373&#8211;380.</P>
<P>3. Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, Knipe DM, Howley PM (eds). Fields' Virology. Philadelphia: Lippincott-Raven, 1996: 1353&#8211;1445.</P>
<P>4. <A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=Bell%20IR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23277079">Bell IR</A>, <A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=Schwartz%20GE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23277079">Schwartz GE</A>. Adaptive network nanomedicine: an integrated model for homeopathic medicine. <I>Front Biosci (Schol Ed)</I> 2013; S<B>5</B>: 685&#8211;708.</P>
<P>5. van Wijk R, Bosman S, van Wijk EP. Thermoluminescence in ultra-high dilution research. <I>J Altern Complement Med</I> 2006; <B>12</B>: 437&#8211;443.</P>
<P>6. Elia V, Napoli E, Niccoli M, Nonatelli L, Ramaglia A, Ventimiglia E. New physico-chemical properties of extremely diluted aqueous solutions. <I>J Therm Anal Calor</I> 2004; <B>78</B>: 331&#8211;342.</P>
<P>7. Demangeat J.-L. NMR water proton relaxation in unheated and heated ultrahigh aqueous dilutions of histamine: Evidence for an air-dependent supramolecular organization of water. J Mol Liq 2009; 144: 32&#8211;39.</P>
<P>8. Editorial commentary. Why comparisons are essential. <I>The James Lind Library</I>, 2007 (<A HREF="http://www.jameslindlibrary.org">www.jameslindlibrary.org</A>)</P>
<P>9. Jacobs J, Jonas WB, Jimenez-Perez M, Crothers D. Homeopathy for childhood diarrhea: combined results and metaanalysis from three randomized, controlled clinical trials. <I>Pediatr Infect Dis J</I> 2003; <B>22</B>: 229&#8211;234.</P>
<P>10. Schneider B, Klein P, Weiser M. Treatment of vertigo with a homeopathic complex remedy compared with usual treatments: a meta-analysis of clinical trials. <I>Arzneimittelforschung</I> 2005; <B>55</B>: 23&#8211;29.</P>
<P>11. Gallucci S et al. v. Boiron Inc. et al. Class Action Settlement Agreement: Case No. 3:11-cv-02039-JAH-NLS. <I>United States District Court: Southern District of California</I>, 2012. (<A HREF="http://www.gilardi.com/boironsettlement/pdf/BRGL_SettlementAgreement.pdf">http://www.gilardi.com/boironsettlement/pdf/BRGL_SettlementAgreement.pdf</A>)</P>
<P>12. <I>Guy Chapman's Blahg</I>. (<A HREF="http://www.chapmancentral.co.uk/blahg/?s=homeopathy">http://www.chapmancentral.co.uk/blahg/?s=homeopathy</A>)</P>
<P>13. Chapman G. Tooth fairy science in the Cochrane Library. (<A HREF="http://www.chapmancentral.co.uk/blahg/2013/01/tooth-fairy-science-in-the-cochrane-library/">http://www.chapmancentral.co.uk/blahg/2013/01/tooth-fairy-science-in-the-cochrane-library/</A>)</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2013-04-16 08:30:59 +1000" MODIFIED_BY="[Empty name]">
<P>RT Mathie, J Frye, P Fisher</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2015-01-14 21:19:25 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-08-07 17:46:43 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-08-07 17:45:02 +1000" MODIFIED_BY="[Empty name]">Details of earlier searches</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-07 17:46:43 +1000" MODIFIED_BY="[Empty name]">
<P>In 1999, the registry of randomised trials for the Complementary Medicine Field of The Cochrane Collaboration was searched using the terms "homeopathy" with "influenza", "respiratory tract", "infection", "cough", "virus" and "fever". This registry had then recently benefited from incorporating trials found during an extremely comprehensive systematic review of homeopathy (<LINK REF="REF-Linde-1997" TYPE="REFERENCE">Linde 1997</LINK>) and it was considered unlikely that further studies existed. Homeopathic manufacturers were contacted for information about other trials.</P>
<P>For the first update of this review, published in Issue 1, 2004, the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 2, 2003), MEDLINE (January 1966 to June 2003) and EMBASE (1980 to June 2003) were searched, but no new trials were found. There were no language restrictions.</P>
<P>For the <LINK REF="REF-Vickers-2006" TYPE="REFERENCE">Vickers 2006</LINK> update, the search remained focused on the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 1, 2006), MEDLINE (January 1966 to February 2006) and EMBASE (1980 to February 2006). See below for details of MEDLINE search strategy. The manufacturers of Oscillococcinum<SUP>®</SUP> were contacted for information, which was provided. There were no language restrictions.</P>
<SUBSECTION>
<HEADING LEVEL="5">MEDLINE (Ovid)</HEADING>
<P>#1. exp HOMEOPATHY/<BR/>#2. homeopath$.mp.<BR/>#3. homoeopath$.mp.<BR/>#4. oscillococcinum.mp.<BR/>#5. or/1-4<BR/>#6. exp INFLUENZA/<BR/>#7. influenza.mp.<BR/>#8. flu.mp.<BR/>#9. exp COUGH/<BR/>#10. cough$.mp.<BR/>#11. exp VIRUSES/<BR/>#12. virus$.mp.<BR/>#13. exp Respiratory Tract Infections/<BR/>#14. exp Respiratory System/<BR/>#15. respiratory tract$.mp.<BR/>#16. exp INFECTION/<BR/># 17. infection$.mp.<BR/># 18. exp FEVER/<BR/># 19. fever$.mp.<BR/># 20. or/6-19<BR/># 21. 5 and 20<BR/># 22. limit 21 to yr=2003-2006</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-08-07 17:50:59 +1000" MODIFIED_BY="[Empty name]">MEDLINE (Ovid)</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-21 00:19:01 +1000" MODIFIED_BY="[Empty name]">
<P>1 oscillococcinum.tw,nm.<BR/>2 "anas barbariae hepatis et cordis extractum".tw,nm.<BR/>3 Homeopathy/<BR/>4 homeopath*.tw.<BR/>5 homoeopath*.tw.<BR/>6 oscillo*.tw,nm.<BR/>7 or/3-6<BR/>8 Influenza, Human/<BR/>9 exp Influenzavirus A/<BR/>10 exp Influenzavirus B/<BR/>11 influenza*.tw.<BR/>12 flu.tw.<BR/>13 Cough/<BR/>14 cough*.tw.<BR/>15 sore throat*.tw.<BR/>16 exp Viruses/<BR/>17 virus*.tw.<BR/>18 Respiratory Tract Infections/<BR/>19 Respiratory System/<BR/>20 exp Infection/<BR/>21 infection*.tw.<BR/>22 (respiratory adj3 (infection* or tract or acute or symptom*)).tw.<BR/>23 exp Fever/<BR/>24 fever*.tw.<BR/>25 runny nose*.tw.<BR/>26 Headache/<BR/>27 headache*.tw.<BR/>28 (pain adj2 (limb* or joint*)).tw.<BR/>29 or/8-28<BR/>30 7 and 29<BR/>31 1 or 2 or 30</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-01-14 21:19:25 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-12-11 18:03:15 +1000" MODIFIED_BY="[Empty name]">Other search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-01-14 21:19:25 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">MEDLINE In-Process &amp; Other Non-Indexed Citations (Ovid)</HEADING>
<P>1 oscillo*.tw.<BR/>2 "anas barbariae".tw.<BR/>3 (homeopath* or homoeopath*).tw.<BR/>4 or/1-3<BR/>5 influenza.tw.<BR/>6 flu.tw.<BR/>7 influenzavirus.tw.<BR/>8 cough*.tw.<BR/>9 sore throat*.tw.<BR/>10 virus*.tw.<BR/>11 respiratory tract infection*.tw.<BR/>12 respiratory infection*.tw.<BR/>13 fever*.tw.<BR/>14 runny nose*.tw.<BR/>15 headache*.tw.<BR/>16 (pain adj2 (limb* or joint*)).tw.<BR/>17 infection*.tw.<BR/>18 or/5-17<BR/>19 4 and 18</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">EMBASE.com</HEADING>
<P>31. #27 AND #30<BR/>30. #28 OR #29<BR/>29. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross-over':ab,ti OR 'cross over':ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR volunteer*:ab,ti OR ((singl* OR doubl*) NEAR/2 (blind* OR mask*)):ab,ti<BR/>28. 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp<BR/>27. #1 OR #2 OR #26<BR/>26. #6 AND #25<BR/>25. #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24<BR/>24. (pain NEAR/2 (limb* OR joint*)):ab,ti<BR/>23. headache*:ab,ti<BR/>22. 'headache'/exp<BR/>21. 'runny nose':ab,ti OR 'runny noses':ab,ti<BR/>20. 'fever'/de<BR/>19. (respiratory NEAR/3 (infection* OR tract OR acute OR symptom*)):ab,ti<BR/>18. infection*:ab,ti<BR/>17. 'infection'/de<BR/>16. 'respiratory system'/de<BR/>15. 'respiratory tract infection'/de OR 'upper respiratory tract infection'/de OR 'lower respiratory tract infection'/de OR 'viral respiratory tract infection'/de<BR/>14. virus*:ab,ti<BR/>13. 'virus'/exp<BR/>12. 'sore throat':ab,ti OR 'sore throats':ab,ti<BR/>11. cough*:ab,ti<BR/>10. 'coughing'/de<BR/>9. influenza*:ab,ti OR flu:ab,ti<BR/>8. 'influenza virus a'/exp OR 'influenza virus b'/exp OR 'swine influenza virus'/de OR 'influenza virus c'/de<BR/>7. 'influenza'/exp<BR/>6. #3 OR #4 OR #5<BR/>5. oscillo*:ab,ti<BR/>4. homeopath*:ab,ti OR homoeopath*:ab,ti<BR/>3. 'homeopathy'/de<BR/>2. 'anas barbariae hepatis':ab,ti<BR/>1. oscillococcinum:ab,ti</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">AMED (Ovid)</HEADING>
<P>1 oscillococcinum.tw.<BR/>2 exp homeopathy/<BR/>3 (homeopath* or homoeopath*).tw.<BR/>4 oscillo*.tw.<BR/>5 or/2-4<BR/>6 influenza/<BR/>7 (influenza* or flu).tw.<BR/>8 cough/<BR/>9 cough*.tw.<BR/>10 sore throat*.tw.<BR/>11 viruses/<BR/>12 virus*.tw.<BR/>13 respiratory tract infections/<BR/>14 respiratory system/<BR/>15 exp infection/<BR/>16 infection*.tw.<BR/>17 (respiratory adj3 (infection* or acute or tract or symptom*)).tw.<BR/>18 fever/<BR/>19 fever*.tw.<BR/>20 runny nose*.tw.<BR/>21 headache/<BR/>22 headache*.tw.<BR/>23 (pain* adj2 (limb* or joint*)).tw.<BR/>24 or/6-23<BR/>25 5 and 24<BR/>26 1 or 25</P>
<P>Web of Science (Thomson Reuters) and LILACS (BIREME) were searched using the term 'oscillococcinum'.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>